Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.

Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA. 1996;93(15):8072–7. https://doi.org/10.1073/pnas.93.15.8072 .

doi: 10.1073/pnas.93.15.8072 pubmed: 8755605 pmcid: 38877

Hayashi T, Su TP. σ-1 Receptors (σ1 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. J Pharmacol Exp Ther. 2003;306(2):718–25. https://doi.org/10.1124/jpet.103.051284 .

doi: 10.1124/jpet.103.051284 pubmed: 12730355

Hayashi T, Su TP. Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc Natl Acad Sci USA. 2001;98(2):491–6. https://doi.org/10.1073/pnas.021413698 .

doi: 10.1073/pnas.021413698 pubmed: 11149946 pmcid: 14614

Kinoshita M, Matsuoka Y, Suzuki T, Mirrielees J, Yang J. Sigma-1 receptor alters the kinetics of Kv1.3 voltage gated potassium channels but not the sensitivity to receptor ligands. Brain Res. 2012;1452:1–9. https://doi.org/10.1016/j.brainres.2012.02.070 .

doi: 10.1016/j.brainres.2012.02.070 pubmed: 22433979 pmcid: 3670091

Brimson JM, Akula KK, Abbas H, Ferry DR, Kulkarni SK, Russell ST, et al. Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression. Sci Rep. 2020;10(1):9251. https://doi.org/10.1038/s41598-020-65849-6 .

doi: 10.1038/s41598-020-65849-6 pubmed: 32514120 pmcid: 7280195

Brimson JM, Brown CA, Safrany ST. Antagonists show GTP-sensitive high-affinity binding to the sigma-1 receptor. Br J Pharmacol. 2011;164(2B):772–80. https://doi.org/10.1111/j.1476-5381.2011.01417.x .

doi: 10.1111/j.1476-5381.2011.01417.x pubmed: 21486275 pmcid: 3188898

Natsvlishvili N, Goguadze N, Zhuravliova E, Mikeladze D. Sigma-1 receptor directly interacts with Rac1-GTPase in the brain mitochondria. BMC Biochem. 2015;16(1):1–7. https://doi.org/10.1186/s12858-015-0040-y .

doi: 10.1186/s12858-015-0040-y

Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323(5916):934–7. https://doi.org/10.1126/science.1166127 .

doi: 10.1126/science.1166127 pubmed: 19213917 pmcid: 2947205

Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs. 2004;18(5):269–84. https://doi.org/10.2165/00023210-200418050-00001 .

doi: 10.2165/00023210-200418050-00001 pubmed: 15089113

Ruoho AE, Chu UB, Ramachandran S, Fontanilla D, Mavlyutov T, Hajipour AR. The ligand binding region of the sigma-1 receptor: studies utilizing photoaffinity probes, sphingosine and N-alkylamines. Curr Pharm Des. 2012;18(7):920–9. https://doi.org/10.2174/138161212799436584 .

doi: 10.2174/138161212799436584 pubmed: 22288412 pmcid: 4440231

Vavers E, Zvejniece L, Maurice T, Dambrova M. Allosteric modulators of sigma-1 receptor: a review. Front Pharmacol. 2019;10:223. https://doi.org/10.3389/fphar.2019.00223 .

doi: 10.3389/fphar.2019.00223 pubmed: 30941035 pmcid: 6433746

Hayashi T, Su TP. The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol. 2005;3(4):267–80. https://doi.org/10.2174/157015905774322516 .

doi: 10.2174/157015905774322516 pubmed: 18369400 pmcid: 2268997

Quirion R, Chicheportiche R, Contreras PC, Johnson KM, Lodge D, Tam SW, et al. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci. 1987;10(11):444–6. https://doi.org/10.1016/0166-2236(87)90094-4 .

doi: 10.1016/0166-2236(87)90094-4

Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MVL, O’Neill M, et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004;64(14):4875–86. https://doi.org/10.1158/0008-5472.CAN-03-3180 .

doi: 10.1158/0008-5472.CAN-03-3180 pubmed: 15256458

Wang L, Prescott AR, Spruce BA, Sanderson J, Duncan G. Sigma receptor antagonists inhibit human lens cell growth and induce pigmentation. Invest Ophthalmol Vis Sci. 2005;46(4):1403–8. https://doi.org/10.1167/iovs.04-1209 .

doi: 10.1167/iovs.04-1209 pubmed: 15790908

Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell. 2007;131(3):596–610. https://doi.org/10.1016/j.cell.2007.08.036 .

doi: 10.1016/j.cell.2007.08.036 pubmed: 17981125

Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of σ1 and σ2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol. 1994;268(1):9–18. https://doi.org/10.1016/0922-4106(94)90115-5 .

doi: 10.1016/0922-4106(94)90115-5 pubmed: 7925616

Wolfe SA Jr, Culp SG, De Souza EB. σ-Receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology. 1989;124(3):1160–72. https://doi.org/10.1210/endo-124-3-1160 .

doi: 10.1210/endo-124-3-1160 pubmed: 2537173

Borde P, Cosgrove N, Charmsaz S, Safrany ST, Young L. An investigation of Sigma-1 receptor expression and ligand-induced endoplasmic reticulum stress in breast cancer. Cancer Gene Ther. 2023;30(2):368–74. https://doi.org/10.1038/s41417-022-00552-4 .

doi: 10.1038/s41417-022-00552-4 pubmed: 36352093

Huang YS, Lu HL, Zhang LJ, Wu Z. Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy. Med Res Rev. 2014;34(3):532–66. https://doi.org/10.1002/med.21297 .

doi: 10.1002/med.21297 pubmed: 23922215

Nicholson H, Mesangeau C, McCurdy CR, Bowen WD. Sigma-2 receptors play a role in cellular metabolism: stimulation of glycolytic hallmarks by CM764 in human SK-N-SH neuroblastoma. J Pharmacol Exp Ther. 2016;356(2):232–43. https://doi.org/10.1124/jpet.115.228387 .

doi: 10.1124/jpet.115.228387 pubmed: 26574517 pmcid: 4746495

Rousseaux CG, Greene SF. Sigma receptors [σRs]: biology in normal and diseased states. J Recept Signal Transduct Res. 2016;36(4):327–88. https://doi.org/10.3109/10799893.2015.1015737 .

doi: 10.3109/10799893.2015.1015737 pubmed: 26056947

Liu C, Yu CF, Wang SC, Li HY, Lin CM, Wang HH, et al. Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor. BMC Cancer. 2019;19(1):473. https://doi.org/10.1186/s12885-019-5700-7 .

doi: 10.1186/s12885-019-5700-7 pubmed: 31109310 pmcid: 6528305

Yang K, Wang C, Sun T. The roles of intracellular chaperone proteins, sigma receptors, in Parkinson’s disease (PD) and major depressive disorder (MDD). Front Pharmacol. 2019;10:528. https://doi.org/10.3389/fphar.2019.00528 .

doi: 10.3389/fphar.2019.00528 pubmed: 31178723 pmcid: 6537631

Georgiadis MO, Karoutzou O, Foscolos AS, Papanastasiou I. Sigma receptor (σR) ligands with antiproliferative and anticancer activity. Molecules. 2017;22:9. https://doi.org/10.3390/molecules22091408 .

doi: 10.3390/molecules22091408

Gebreselassie D, Bowen WD. Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. Eur J Pharmacol. 2004;493(1–3):19–28. https://doi.org/10.1016/j.ejphar.2004.04.005 .

doi: 10.1016/j.ejphar.2004.04.005 pubmed: 15189760

Munro S. Lipid rafts: elusive or illusive? Cell. 2003;115(4):377–88. https://doi.org/10.1016/S0092-8674(03)00882-1 .

doi: 10.1016/S0092-8674(03)00882-1 pubmed: 14622593

Alon A, Lyu J, Braz JM, Tummino TA, Craik V, O’Meara MJ, et al. Structures of the σ2 receptor enable docking for bioactive ligand discovery. Nature. 2021;600(7890):759–64. https://doi.org/10.1038/s41586-021-04175-x .

doi: 10.1038/s41586-021-04175-x pubmed: 34880501 pmcid: 8867396

Terada K, Migita K, Matsushima Y, Kamei C. Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders. Neural Regen Res. 2019;14(11):1893–4. https://doi.org/10.4103/1673-5374.259609 .

doi: 10.4103/1673-5374.259609 pubmed: 31290438 pmcid: 6676876

Abate C, Niso M, Berardi F. Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations. Future Med Chem. 2018;10(16):1997–2018. https://doi.org/10.4155/fmc-2018-0072 .

doi: 10.4155/fmc-2018-0072 pubmed: 29966437

Cantonero C, Camello PJ, Abate C, Berardi F, Salido GM, Rosado JA, et al. NO1, a new Sigma 2 receptor/TMEM97 fluorescent ligand, downregulates SOCE and promotes apoptosis in the triple negative breast cancer cell lines. Cancers (Basel). 2020;12(2):257. https://doi.org/10.3390/cancers12020257 .

doi: 10.3390/cancers12020257 pubmed: 31973006 pmcid: 7072710

Zeng C, Vangveravong S, McDunn JE, Hawkins WG, Mach RH. Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer. Br J Cancer. 2013;109(9):2368–77. https://doi.org/10.1038/bjc.2013.593 .

doi: 10.1038/bjc.2013.593 pubmed: 24104966 pmcid: 3817331

Zeng C, Riad A, Mach RH. The biological function of Sigma-2 receptor/TMEM97 and its utility in PET imaging studies in cancer. Cancers (Basel). 2020;12(7):1877. https://doi.org/10.3390/cancers12071877 .

doi: 10.3390/cancers12071877 pubmed: 32668577 pmcid: 7409002

2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17(3):327–406. https://doi.org/10.1002/alz.12328 .

Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362(4):329–44. https://doi.org/10.1056/NEJMra0909142 .

doi: 10.1056/NEJMra0909142 pubmed: 20107219

Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol. 2011;68(8):1062–4. https://doi.org/10.1001/archneurol.2011.70 .

doi: 10.1001/archneurol.2011.70 pubmed: 21482918

Soria Lopez JA, González HM, Léger GC. Alzheimer’s disease. Handb Clin Neurol. 2019;167:231–55. https://doi.org/10.1016/b978-0-12-804766-8.00013-3 .

doi: 10.1016/b978-0-12-804766-8.00013-3 pubmed: 31753135

Hampel H, Caraci F, Cuello AC, Caruso G, Nisticò R, Corbo M, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer’s disease. Front Immunol. 2020;11:456. https://doi.org/10.3389/fimmu.2020.00456 .

doi: 10.3389/fimmu.2020.00456 pubmed: 32296418 pmcid: 7137904

Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L, et al. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020;26(5):769–80. https://doi.org/10.1038/s41591-020-0815-6 .

doi: 10.1038/s41591-020-0815-6 pubmed: 32284590 pmcid: 7405761

Sánchez-Fernández C, Entrena JM, Baeyens JM, Cobos EJ. Sigma-1 receptor antagonists: a new class of neuromodulatory analgesics. Adv Exp Med Biol. 2017;964:109–32. https://doi.org/10.1007/978-3-319-50174-1_9 .

doi: 10.1007/978-3-319-50174-1_9 pubmed: 28315268

Su TP, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem. 2003;10(20):2073–80. https://doi.org/10.2174/0929867033456783 .

doi: 10.2174/0929867033456783 pubmed: 12871086

De B, Nadal X, Portillo-salido E, Sánchez-arroyos R, Ovalle S, Palacios G, et al. Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain. 2009;145(3):294–303. https://doi.org/10.1016/j.pain.2009.05.013 .

doi: 10.1016/j.pain.2009.05.013

Nieto FR, Cendán CM, Sánchez-Fernández C, Cobos EJ, Entrena JM, Tejada MA, et al. Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice. J Pain. 2012;13(11):1107–21. https://doi.org/10.1016/j.jpain.2012.08.006 .

doi: 10.1016/j.jpain.2012.08.006 pubmed: 23063344

Zamanillo D, Romero L, Merlos M, Vela JM. Sigma 1 receptor: a new therapeutic target for pain. Eur J Pharmacol. 2013;716(1–3):78–93. https://doi.org/10.1016/j.ejphar.2013.01.068 .

doi: 10.1016/j.ejphar.2013.01.068 pubmed: 23500210

Kawamura K, Kimura Y, Tsukada H, Kobayashi T, Nishiyama S, Kakiuchi T, et al. An increase of sigma1 receptors in the aged monkey brain. Neurobiol Aging. 2003;24(5):745–52. https://doi.org/10.1016/S0197-4580(02)00152-5 .

doi: 10.1016/S0197-4580(02)00152-5 pubmed: 12885582

Wallace DR, Mactutus CF, Booze RM. Sigma binding sites identified by [3H] DTG are elevated in aged Fischer-344× Brown Norway (F1) rats. Synapse. 2000;35(4):311–3. https://doi.org/10.1002/(SICI)1098-2396(20000315)35:4%3c311::AID-SYN9%3e3.0.CO;2-5 .

doi: 10.1002/(SICI)1098-2396(20000315)35:4<311::AID-SYN9>3.0.CO;2-5 pubmed: 10657041

Ishiwata K, Kobayashi T, Kawamura K, Matsuno K. Age-related changes of the binding of [3H] SA4503 to sigma1 receptors in the rat brain. Ann Nucl Med. 2003;17(1):73–7. https://doi.org/10.1007/BF02988264 .

doi: 10.1007/BF02988264 pubmed: 12691135

Horsager J, Fedorova TD, Berge NV, Klinge MW, Knudsen K, Hansen AK, et al. Cardiac 11C-donepezil binding increases with age in healthy humans: potentially signifying Sigma-1 receptor upregulation. J Cardiovasc Pharmacol Ther. 2019;24(4):365–70. https://doi.org/10.1177/1074248419838509 .

doi: 10.1177/1074248419838509 pubmed: 30913922

Norbury R, Travis MJ, Erlandsson K, Waddington W, Owens J, Pimlott S, et al. In vivo imaging of muscarinic receptors in the aging female brain with (R, R)[123I]-I-QNB and single photon emission tomography. Exp Gerontol. 2005;40(3):137–45. https://doi.org/10.1016/j.exger.2004.10.002 .

doi: 10.1016/j.exger.2004.10.002 pubmed: 15763390

Sheline YI, Mintun MA, Moerlein SM, Snyder AZ. Greater loss of 5-HT2A receptors in midlife than in late life. Am J Psychiatry. 2002;159(3):430–5. https://doi.org/10.1176/appi.ajp.159.3.430 .

doi: 10.1176/appi.ajp.159.3.430 pubmed: 11870007

Inoue M, Suhara T, Sudo Y, Okubo Y, Yasuno F, Kishimoto T, et al. Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. Life Sci. 2001;69(9):1079–84. https://doi.org/10.1016/s0024-3205(01)01205-x .

doi: 10.1016/s0024-3205(01)01205-x pubmed: 11508650

Brimson JM, Brimson S, Chomchoei C, Tencomnao T. Using Sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opin Ther Targets. 2020;24(10):1009–28. https://doi.org/10.1080/14728222.2020.1805435 .

doi: 10.1080/14728222.2020.1805435 pubmed: 32746649

Prasanth MI, Malar D, Tencomnao T, Brimson J. The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer’s Disease. Expert Opin Ther Targets. 2021;25(5):401–14. https://doi.org/10.1080/14728222.2021.1939681 .

doi: 10.1080/14728222.2021.1939681 pubmed: 34110944

Mishina M, Ohyama M, Ishii K, Kitamura S, Kimura Y, Oda K, et al. Low density of sigma 1 receptors in early Alzheimer’s disease. Ann Nucl Med. 2008;22(3):151–6. https://doi.org/10.1007/s12149-007-0094-z .

doi: 10.1007/s12149-007-0094-z pubmed: 18498028

Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42(1):85–94. https://doi.org/10.1002/ana.410420114 .

doi: 10.1002/ana.410420114 pubmed: 9225689

Uchida N, Ujike H, Tanaka Y, Sakai A, Yamamoto M, Fujisawa Y, et al. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. Am J Geriatr Psychiatry. 2005;13(12):1062–6. https://doi.org/10.1176/appi.ajgp.13.12.1062 .

doi: 10.1176/appi.ajgp.13.12.1062 pubmed: 16319298

Maruszak A, Safranow K, Gacia M, Gabryelewicz T, Słowik A, Styczyńska M, et al. Sigma receptor type 1 gene variation in a group of polish patients with Alzheimer’s disease and mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23(6):432–8. https://doi.org/10.1159/000101990 .

doi: 10.1159/000101990 pubmed: 17457031

Huang Y, Zheng L, Halliday G, Dobson-Stone C, Wang Y, Tang H-D, et al. Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer’s disease. Curr Alzheimer Res. 2011;8(7):765–70. https://doi.org/10.2174/156720511797633232 .

doi: 10.2174/156720511797633232 pubmed: 21605063

Feher A, Juhasz A, Laszlo A, Kalman J Jr, Pakaski M, Kalman J, et al. Association between a variant of the sigma-1 receptor gene and Alzheimer’s disease. Neurosci Lett. 2012;517(2):136–9. https://doi.org/10.1016/j.neulet.2012.04.046 .

doi: 10.1016/j.neulet.2012.04.046 pubmed: 22561649

Jin JL, Fang M, Zhao YX, Liu XY. Roles of sigma-1 receptors in Alzheimer’s disease. Int J Clin Exp Med. 2015;8(4):4808–20.

pubmed: 26131055 pmcid: 4484039

Tsai SY, Hayashi T, Harvey BK, Wang Y, Wu WW, Shen RF, et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1•GTP pathway. Proc Natl Acad Sci USA. 2009;106(52):22468–73. https://doi.org/10.1073/pnas.0909089106 .

doi: 10.1073/pnas.0909089106 pubmed: 20018732 pmcid: 2792161

Fisher A, Bezprozvanny I, Wu L, Ryskamp DA, Bar-Ner N, Natan N, et al. AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer’s disease. Neurodegener Dis. 2016;16(1–2):95–110. https://doi.org/10.1159/000440864 .

doi: 10.1159/000440864 pubmed: 26606130

Ryskamp D, Wu L, Wu J, Kim D, Rammes G, Geva M, et al. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer’s disease by acting on the sigma-1 receptor. Neurobiol Dis. 2019;124:489–504. https://doi.org/10.1016/j.nbd.2018.12.022 .

doi: 10.1016/j.nbd.2018.12.022 pubmed: 30594810

Tsai SYA, Pokrass MJ, Klauer NR, Nohara H, Su TP. Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid. Proc Natl Acad Sci USA. 2015;112(21):6742–7. https://doi.org/10.1073/pnas.1422001112 .

doi: 10.1073/pnas.1422001112 pubmed: 25964330 pmcid: 4450430

Christ MG, Huesmann H, Nagel H, Kern A, Behl C. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. Cells. 2019;8(3):211. https://doi.org/10.3390/cells8030211 .

doi: 10.3390/cells8030211 pubmed: 30832324 pmcid: 6468724

Romeo MA, Faggioni A, Cirone M. Could autophagy dysregulation link neurotropic viruses to Alzheimer’s disease? Neural Regen Res. 2019;14(9):1503–6. https://doi.org/10.4103/1673-5374.253508 .

doi: 10.4103/1673-5374.253508 pubmed: 31089040 pmcid: 6557098

McBrayer M, Nixon RA. Lysosome and calcium dysregulation in Alzheimer’s disease: partners in crime. Biochem Soc Trans. 2013;41(6):1495–502. https://doi.org/10.1042/BST20130201 .

doi: 10.1042/BST20130201 pubmed: 24256243 pmcid: 3960943

Uddin MS, Stachowiak A, Mamun AA, Tzvetkov NT, Takeda S, Atanasov AG, et al. Autophagy and Alzheimer’s disease: from molecular mechanisms to therapeutic implications. Front Aging Neurosci. 2018;10:04. https://doi.org/10.3389/fnagi.2018.00004 .

doi: 10.3389/fnagi.2018.00004 pubmed: 29441009 pmcid: 5797541

Callens M, Loncke J, Bultynck G. Dysregulated Ca2+ homeostasis as a central theme in neurodegeneration: lessons from Alzheimer’s disease and Wolfram syndrome. Cells. 2022;11(12):1963. https://doi.org/10.3390/cells11121963 .

doi: 10.3390/cells11121963 pubmed: 35741091 pmcid: 9221778

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216–23. https://doi.org/10.1016/S0140-6736(08)61075-2 .

doi: 10.1016/S0140-6736(08)61075-2 pubmed: 18640458

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. https://doi.org/10.1056/NEJMoa2212948 .

doi: 10.1056/NEJMoa2212948 pubmed: 36449413

Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci. 2007;27(4):796–807. https://doi.org/10.1523/JNEUROSCI.3501-06.2007 .

doi: 10.1523/JNEUROSCI.3501-06.2007 pubmed: 17251419 pmcid: 6672917

Pannuzzo M. On the physiological/pathological link between Aβ peptide, cholesterol, calcium ions and membrane deformation: a molecular dynamics study. Biochim Biophys Acta. 2016;1858(6):1380–9. https://doi.org/10.1016/j.bbamem.2016.03.018 .

doi: 10.1016/j.bbamem.2016.03.018 pubmed: 27003127

Games D, Adams D, Alessandrini R, Barbour R, Borthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995;373(6514):523–7. https://doi.org/10.1038/373523a0 .

doi: 10.1038/373523a0 pubmed: 7845465

Brimson JM. The Pharmacology of the Sigma-1 Receptor [Doctoral Thesis]. In: The University of Bath online repository. 2010. http://opus.bath.ac.uk/19712/ . Accessed 1 Dec 2022.

Katnik C, Guerrero WR, Pennypacker KR, Herrera Y, Cuevas J. Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia. J Pharmacol Exp Ther. 2006;319(3):1355–65. https://doi.org/10.1124/jpet.106.107557 .

doi: 10.1124/jpet.106.107557 pubmed: 16988055

Delprat B, Crouzier L, Su TP, Maurice T. At the crossing of ER stress and MAMs: a key role of sigma-1 receptor? Adv Exp Med Biol. 2020;1131:699–718. https://doi.org/10.1007/978-3-030-12457-1_2878 .

doi: 10.1007/978-3-030-12457-1_2878 pubmed: 31646531

Hayashi T, Rizzuto R, Hajnoczky G, Su TP. MAM: more than just a housekeeper. Trends Cell Biol. 2009;19(2):81–8. https://doi.org/10.1016/j.tcb.2008.12.00279 .

doi: 10.1016/j.tcb.2008.12.00279 pubmed: 19144519 pmcid: 2750097

Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512–21. https://doi.org/10.1111/epi.13709 .

doi: 10.1111/epi.13709 pubmed: 28276062 pmcid: 5386840

Specchio N, Curatolo P. Developmental and epileptic encephalopathies: what we do and do not know. Brain. 2021;144(1):32–43. https://doi.org/10.1093/brain/awaa371 .

doi: 10.1093/brain/awaa371 pubmed: 33279965

Raga S, Specchio N, Rheims S, Wilmshurst JM. Developmental and epileptic encephalopathies: recognition and approaches to care. Epileptic Disord. 2021;23(1):40–52. https://doi.org/10.1684/epd.2021.1244 .

doi: 10.1684/epd.2021.1244 pubmed: 33632673

Scheffer IE, Liao J. Deciphering the concepts behind “Epileptic encephalopathy” and “Developmental and epileptic encephalopathy.” Eur J Paediatr Neurol. 2020;24:11–4. https://doi.org/10.1016/j.ejpn.2019.12.023 .

doi: 10.1016/j.ejpn.2019.12.023 pubmed: 31926847

Trivisano M, Specchio N. What are the epileptic encephalopathies? Curr Opin Neurol. 2020;33(2):179–84. https://doi.org/10.1097/wco.0000000000000793 .

doi: 10.1097/wco.0000000000000793 pubmed: 32049741

EPX-100 (Clemizole Hydrochloride) as add-on therapy to control convulsive seizures in patients with Dravet syndrome (ARGUS). In: NIH U.S. National Library of Medicine. 2020. https://clinicaltrials.gov/ct2/show/NCT04462770. Accessed 1 Dec 2022.

Griffin A, Hamling KR, Knupp K, Hong S, Lee LP, Baraban SC. Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain. 2017;140(3):669–83. https://doi.org/10.1093/brain/aww342 .

doi: 10.1093/brain/aww342 pubmed: 28073790 pmcid: 6075536

Vasquez A, Buraniqi E, Wirrell EC. New and emerging pharmacologic treatments for developmental and epileptic encephalopathies. Curr Opin Neurol. 2022;35(2):145–54. https://doi.org/10.1097/wco.0000000000001029 .

doi: 10.1097/wco.0000000000001029 pubmed: 35102126

Miziak B, Czuczwar S. Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome. Expert Opin Drug Discov. 2021;16(5):579–93. https://doi.org/10.1080/17460441.2021.1857722 .

doi: 10.1080/17460441.2021.1857722 pubmed: 33275464

Samanta D. Changing landscape of Dravet syndrome management: an overview. Neuropediatrics. 2020;51(2):135–45. https://doi.org/10.1055/s-0040-1701694 .

doi: 10.1055/s-0040-1701694 pubmed: 32079034

Martin P, Reeder T, Sourbron J, de Witte PAM, Gammaitoni AR, Galer BS. An emerging role for Sigma-1 receptors in the treatment of developmental and epileptic encephalopathies. Int J Mol Sci. 2021;22(16):8416. https://doi.org/10.3390/ijms22168416 .

doi: 10.3390/ijms22168416 pubmed: 34445144 pmcid: 8395113

Vavers E, Zvejniece B, Stelfa G, Svalbe B, Vilks K, Kupats E, et al. Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased susceptibility to seizures. Neurobiol Dis. 2021;150:105244. https://doi.org/10.1016/j.nbd.2020.105244 .

doi: 10.1016/j.nbd.2020.105244 pubmed: 33385516

Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell. 2004;15(1):95–105. https://doi.org/10.1016/j.molcel.2004.06.029 .

doi: 10.1016/j.molcel.2004.06.029 pubmed: 15225551

Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington’s disease. Nat Neurosci. 2010;13(5):567–76. https://doi.org/10.1038/nn.2528 .

doi: 10.1038/nn.2528 pubmed: 20383138 pmcid: 2860687

Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest. 2011;121(2):493–9. https://doi.org/10.1172/JCI45691 .

doi: 10.1172/JCI45691 pubmed: 21285522 pmcid: 3026743

Caron NS, Wright GEB, Hayden MR. Huntington Disease. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al., editors. GeneReviews, University of Washington, Seattle. 1993. https://www.ncbi.nlm.nih.gov/books/NBK1305/ .

Frank S. Treatment of Huntington’s disease. Neurotherapeutics. 2014;11(1):153–60. https://doi.org/10.1007/s13311-013-0244-z .

doi: 10.1007/s13311-013-0244-z pubmed: 24366610

Miki Y, Tanji K, Mori F, Wakabayashi K. Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington’s disease. Neurobiol Dis. 2015;74:25–31. https://doi.org/10.1016/j.nbd.2014.11.005 .

doi: 10.1016/j.nbd.2014.11.005 pubmed: 25449906

Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, et al. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis. 2017;97:46–59. https://doi.org/10.1016/j.nbd.2016.10.006 .

doi: 10.1016/j.nbd.2016.10.006 pubmed: 27818324

Jabłońska M, Grzelakowska K, Wiśniewski B, Mazur E, Leis K, Gałązka P. Pridopidine in the treatment of Huntington’s disease. Rev Neurosci. 2020;31(4):441–51. https://doi.org/10.1515/revneuro-2019-0085 .

doi: 10.1515/revneuro-2019-0085 pubmed: 32083454

Nguyen L, Lucke-Wold BP, Mookerjee SA, Cavendish JZ, Robson MJ, Scandinaro AL, et al. Role of sigma-1 receptors in neurodegenerative diseases. J Pharmacol Sci. 2015;127(1):17–29. https://doi.org/10.1016/j.jphs.2014.12.005 .

doi: 10.1016/j.jphs.2014.12.005 pubmed: 25704014

Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10(11):661–70. https://doi.org/10.1038/nrneurol.2014.184 .

doi: 10.1038/nrneurol.2014.184 pubmed: 25311585

Machts J, Keute M, Kaufmann J, Schreiber S, Kasper E, Petri S, et al. Longitudinal clinical and neuroanatomical correlates of memory impairment in motor neuron disease. Neuroimage Clin. 2021;29:102545. https://doi.org/10.1016/j.nicl.2020.102545 .

doi: 10.1016/j.nicl.2020.102545 pubmed: 33387861

Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med. 2017;19(3):267–74. https://doi.org/10.1038/gim.2016.107 .

doi: 10.1038/gim.2016.107 pubmed: 27537704

van den Bos MAJ, Geevasinga N, Higashihara M, Menon P, Vucic S. Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques. Int J Mol Sci. 2019;20(11):2818. https://doi.org/10.3390/ijms20112818 .

doi: 10.3390/ijms20112818 pubmed: 31185581 pmcid: 6600525

Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585–91. https://doi.org/10.1056/nejm199403033300901 .

doi: 10.1056/nejm199403033300901 pubmed: 8302340

Heo YA. Sodium phenylbutyrate and ursodoxicoltaurine: first approval. CNS Drugs. 2022;36(9):1007–13. https://doi.org/10.1007/s40263-022-00945-x .

doi: 10.1007/s40263-022-00945-x pubmed: 35907175

Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733–48. https://doi.org/10.1002/med.21528 .

doi: 10.1002/med.21528 pubmed: 30101496

Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1–2):5–14. https://doi.org/10.1080/21678421.2019.1632346 .

doi: 10.1080/21678421.2019.1632346 pubmed: 31280619

Latham BD, Oskin DS, Crouch RD, Vergne MJ, Jackson KD. Cytochromes P450 2C8 and 3A catalyze the metabolic activation of the tyrosine kinase inhibitor masitinib. Chem Res Toxicol. 2022;35(9):1467–81. https://doi.org/10.1021/acs.chemrestox.2c00057 .

doi: 10.1021/acs.chemrestox.2c00057 pubmed: 36048877

Casanovas A, Salvany S, Lahoz V, Tarabal O, Piedrafita L, Sabater R, et al. Neuregulin 1-ErbB module in C-bouton synapses on somatic motor neurons: molecular compartmentation and response to peripheral nerve injury. Sci Rep. 2017;7:40155. https://doi.org/10.1038/srep40155 .

doi: 10.1038/srep40155 pubmed: 28065942 pmcid: 5220293

Herrando-Grabulosa M, Gaja-Capdevila N, Vela JM, Navarro X. Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis. Br J Pharmacol. 2021;178(6):1336–52. https://doi.org/10.1111/bph.15224 .

doi: 10.1111/bph.15224 pubmed: 32761823

Mavlyutov TA, Epstein ML, Liu P, Verbny YI, Ziskind-Conhaim L, Ruoho AE. Development of the sigma-1 receptor in C-terminals of motoneurons and colocalization with the N, N′-dimethyltryptamine forming enzyme, indole-N-methyl transferase. Neuroscience. 2012;206:60–8. https://doi.org/10.1016/j.neuroscience.2011.12.040 .

doi: 10.1016/j.neuroscience.2011.12.040 pubmed: 22265729

Mavlyutov TA, Epstein ML, Andersen KA, Ziskind-Conhaim L, Ruoho AE. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience. 2010;167(2):247–55. https://doi.org/10.1016/j.neuroscience.2010.02.022 .

doi: 10.1016/j.neuroscience.2010.02.022 pubmed: 20167253

Watanabe S, Ilieva H, Tamada H, Nomura H, Komine O, Endo F, et al. Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR 1-and SOD 1-linked ALS. EMBO Mol Med. 2016;8(12):1421–37. https://doi.org/10.15252/emmm.201606403 .

doi: 10.15252/emmm.201606403 pubmed: 27821430 pmcid: 5167132

Couly S, Khalil B, Viguier V, Roussel J, Maurice T, Liévens J-C. Sigma-1 receptor is a key genetic modulator in amyotrophic lateral sclerosis. Hum Mol Genet. 2020;29(4):529–40. https://doi.org/10.1093/hmg/ddz267 .

doi: 10.1093/hmg/ddz267 pubmed: 31696229

Vollrath J, Sechi A, Dreser A, Katona I, Wiemuth D, Vervoorts J, et al. Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances. Cell Death Dis. 2014;5(6):e1290. https://doi.org/10.1038/cddis.2014.243 .

doi: 10.1038/cddis.2014.243 pubmed: 24922074 pmcid: 4611717

Dreser A, Vollrath JT, Sechi A, Johann S, Roos A, Yamoah A, et al. The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins. Cell Death Differ. 2017;24(10):1655–71. https://doi.org/10.1038/cdd.2017.88 .

doi: 10.1038/cdd.2017.88 pubmed: 28622300 pmcid: 5596426

Mavlyutov TA, Epstein ML, Verbny YI, Huerta MS, Zaitoun I, Ziskind-Conhaim L, et al. Lack of sigma-1 receptor exacerbates ALS progression in mice. Neuroscience. 2013;240:129–34. https://doi.org/10.1016/j.neuroscience.2013.02.035 .

doi: 10.1016/j.neuroscience.2013.02.035 pubmed: 23458708

Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol. 2011;70(6):913–9. https://doi.org/10.1002/ana.22534 .

doi: 10.1002/ana.22534 pubmed: 21842496

Fukunaga K, Shinoda Y, Tagashira H. The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis. J Pharmacol Sci. 2015;127(1):36–41. https://doi.org/10.1016/j.jphs.2014.12.012 .

doi: 10.1016/j.jphs.2014.12.012 pubmed: 25704016

Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010;30(2):639–49. https://doi.org/10.1523/JNEUROSCI.4988-09.2010 .

doi: 10.1523/JNEUROSCI.4988-09.2010 pubmed: 20071528 pmcid: 2821110

Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:25. https://doi.org/10.3389/fnmol.2019.00025 .

doi: 10.3389/fnmol.2019.00025 pubmed: 30837838 pmcid: 6382748

Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20–38. https://doi.org/10.1002/ana.23937 .

doi: 10.1002/ana.23937 pubmed: 23686809 pmcid: 3785076

Lee P-T, Liévens J-C, Wang S-M, Chuang J-Y, Khalil B, Wu H-E, et al. Sigma-1 receptor chaperones rescue nucleocytoplasmic transport deficit seen in cellular and Drosophila ALS/FTD models. Nat Commun. 2020;11(1):5580. https://doi.org/10.1038/s41467-020-19396-3 .

doi: 10.1038/s41467-020-19396-3 pubmed: 33149115 pmcid: 7642387

Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(Pt 5):1175–89. https://doi.org/10.1093/brain/awp070 .

doi: 10.1093/brain/awp070 pubmed: 19339255 pmcid: 2677799

McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765–79. https://doi.org/10.1001/jama.2020.26858 .

doi: 10.1001/jama.2020.26858 pubmed: 33620411

Krupp L. Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler. 2006;12(4):367–8. https://doi.org/10.1191/135248506ms1373ed .

doi: 10.1191/135248506ms1373ed pubmed: 16900749

Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010;33(8):1061–7. https://doi.org/10.1093/sleep/33.8.1061 .

doi: 10.1093/sleep/33.8.1061 pubmed: 20815187 pmcid: 2910465

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898–904. https://doi.org/10.1056/nejm200009283431301 .

doi: 10.1056/nejm200009283431301 pubmed: 11006365

Lycke J. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord. 2015;8(6):274–93. https://doi.org/10.1177/1756285615605429 .

doi: 10.1177/1756285615605429 pubmed: 26600872 pmcid: 4643868

Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. https://doi.org/10.1056/NEJMoa0909494 .

doi: 10.1056/NEJMoa0909494 pubmed: 20089952

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–73. https://doi.org/10.1016/s0140-6736(18)30475-6 .

doi: 10.1016/s0140-6736(18)30475-6 pubmed: 29576505

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009–20. https://doi.org/10.1016/s1474-4422(19)30239-x .

doi: 10.1016/s1474-4422(19)30239-x pubmed: 31492651

Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268–76. https://doi.org/10.1212/wnl.45.7.1268 .

doi: 10.1212/wnl.45.7.1268 pubmed: 7617181

Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–56. https://doi.org/10.1016/s1474-4422(13)70308-9 .

doi: 10.1016/s1474-4422(13)70308-9 pubmed: 24461574

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–26. https://doi.org/10.1056/NEJMoa0902533 .

doi: 10.1056/NEJMoa0902533 pubmed: 20089960

Palacios G, Muro A, Verdú E, Pumarola M, Vela JM. Immunohistochemical localization of the sigma1 receptor in Schwann cells of rat sciatic nerve. Brain Res. 2004;1007(1–2):65–70. https://doi.org/10.1016/j.brainres.2004.02.013 .

doi: 10.1016/j.brainres.2004.02.013 pubmed: 15064136

Hayashi T, Su T-P. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. Proc Natl Acad Sci USA. 2004;101(41):14949–54. https://doi.org/10.1073/pnas.0402890101 .

doi: 10.1073/pnas.0402890101 pubmed: 15466698 pmcid: 522002

Zhemkov V, Geva M, Hayden MR, Bezprozvanny I. Sigma-1 receptor (S1R) interaction with cholesterol: mechanisms of S1R activation and its role in neurodegenerative diseases. Int J Mol Sci. 2021;22(8):4082. https://doi.org/10.3390/ijms22084082 .

doi: 10.3390/ijms22084082 pubmed: 33920913 pmcid: 8071319

Berghoff SA, Spieth L, Saher G. Local cholesterol metabolism orchestrates remyelination. Trends Neurosci. 2022;45(4):272–83. https://doi.org/10.1016/j.tins.2022.01.001 .

doi: 10.1016/j.tins.2022.01.001 pubmed: 35153084

Kenche H, Singh M, Smith J, Shen K. Neuronal mitochondrial dysfunction in a cellular model of circadian rhythm disruption is rescued by donepezil. Biochem Biophys Res Commun. 2021;567:56–62. https://doi.org/10.1016/j.bbrc.2021.06.029 .

doi: 10.1016/j.bbrc.2021.06.029 pubmed: 34144501

Oxombre B, Lee-Chang C, Duhamel A, Toussaint M, Giroux M, Donnier-Maréchal M, et al. High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. Br J Pharmacol. 2015;172(7):1769–82. https://doi.org/10.1111/bph.13037 .

doi: 10.1111/bph.13037 pubmed: 25521311 pmcid: 4376455

Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson’s disease: recent advancement. Neurosci Bull. 2017;33(5):585–97. https://doi.org/10.1007/s12264-017-0183-5 .

doi: 10.1007/s12264-017-0183-5 pubmed: 28936761 pmcid: 5636742

Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, et al. Finding useful biomarkers for Parkinson’s disease. Sci Transl Med. 2018;10(454):eaam6003. https://doi.org/10.1126/scitranslmed.aam6003 .

doi: 10.1126/scitranslmed.aam6003 pubmed: 30111645 pmcid: 6097233

Li T, Le W. Biomarkers for Parkinson’s disease: how good are they? Neurosci Bull. 2020;36(2):183–94. https://doi.org/10.1007/s12264-019-00433-1 .

doi: 10.1007/s12264-019-00433-1 pubmed: 31646434

Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–303. https://doi.org/10.1016/s0140-6736(21)00218-x .

doi: 10.1016/s0140-6736(21)00218-x pubmed: 33848468

Parkinson disease. In: World Health Organization website. 2022. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease . Accessed 1 Dec 2022.

LeWitt PA. Levodopa therapy for Parkinson’s disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64–72. https://doi.org/10.1002/mds.26082 .

doi: 10.1002/mds.26082 pubmed: 25449210

Nonnekes J, Timmer MH, de Vries NM, Rascol O, Helmich RC, Bloem BR. Unmasking levodopa resistance in Parkinson’s disease. Mov Disord. 2016;31(11):1602–9. https://doi.org/10.1002/mds.26712 .

doi: 10.1002/mds.26712 pubmed: 27430479

Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683–97. https://doi.org/10.1016/S0140-6736(15)00462-6 .

doi: 10.1016/S0140-6736(15)00462-6 pubmed: 26595642 pmcid: 5792067

Aarsland D, Andersen K, Larsen J, Lolk A, Nielsen H, Kragh-Sørensen P. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology. 2001;56(6):730–6. https://doi.org/10.1212/wnl.56.6.730 .

doi: 10.1212/wnl.56.6.730 pubmed: 11274306

Mishina M, Ishiwata K, Ishii K, Kitamura S, Kimura Y, Kawamura K, et al. Function of sigma 1 receptors in Parkinson’s disease. Acta Neurol Scand. 2005;112(2):103–7. https://doi.org/10.1111/j.1600-0404.2005.00432.x .

doi: 10.1111/j.1600-0404.2005.00432.x pubmed: 16008536

Hong J, Wang L, Zhang T, Zhang B, Chen L. Sigma-1 receptor knockout increases α-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra. Neurobiol Aging. 2017;59:171–83. https://doi.org/10.1016/j.neurobiolaging.2017.08.007 .

doi: 10.1016/j.neurobiolaging.2017.08.007 pubmed: 28870519

Luo Y, Roth GS. The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration. Antioxid Redox Signal. 2000;2(3):449–60. https://doi.org/10.1089/15230860050192224 .

doi: 10.1089/15230860050192224 pubmed: 11229358

Mori T, Hayashi T, Su TP. Compromising σ-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-κB/Bcl-2-dependent mechanism: Potential relevance to Parkinson’s disease. J Pharmacol Exp Ther. 2012;341(3):663–71. https://doi.org/10.1124/jpet.111.190868 .

doi: 10.1124/jpet.111.190868 pubmed: 22399814 pmcid: 3362887

Cagnin M, Ozzano M, Bellio N, Fiorentino I, Follo C, Isidoro C. Dopamine induces apoptosis in APPswe-expressing Neuro2A cells following Pepstatin-sensitive proteolysis of APP in acid compartments. Brain Res. 2012;1471:102–17. https://doi.org/10.1016/j.brainres.2012.06.025 .

doi: 10.1016/j.brainres.2012.06.025 pubmed: 22771396

Brimson JM, Safrany ST, Qassam H, Tencomnao T. Dipentylammonium binds to the Sigma-1 receptor and protects against glutamate toxicity, attenuates dopamine toxicity and potentiates neurite outgrowth in various cultured cell lines. Neurotox Res. 2018;34(2):263–72. https://doi.org/10.1007/s12640-018-9883-5 .

doi: 10.1007/s12640-018-9883-5 pubmed: 29589276

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. https://doi.org/10.1038/nrdp.2017.13 .

doi: 10.1038/nrdp.2017.13 pubmed: 28332488

Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology. 1996;47(6 Suppl 3):S161–70. https://doi.org/10.1212/wnl.47.6_suppl_3.161s .

doi: 10.1212/wnl.47.6_suppl_3.161s pubmed: 8959985

Cristóvão AC, Guhathakurta S, Bok E, Je G, Yoo SD, Choi D-H, et al. NADPH oxidase 1 mediates α-synucleinopathy in Parkinson’s disease. J Neurosci. 2012;32(42):14465–77. https://doi.org/10.1523/JNEUROSCI.2246-12.2012 .

doi: 10.1523/JNEUROSCI.2246-12.2012 pubmed: 23077033 pmcid: 3501265

Guo JD, Zhao X, Li Y, Li GR, Liu XL. Damage to dopaminergic neurons by oxidative stress in Parkinson’s disease. Int J Mol Med. 2018;41(4):1817–25. https://doi.org/10.3892/ijmm.2018.3406 .

doi: 10.3892/ijmm.2018.3406 pubmed: 29393357

Pal A, Fontanilla D, Gopalakrishnan A, Chae Y-K, Markley JL, Ruoho AE. The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur J Pharmacol. 2012;682(1–3):12–20. https://doi.org/10.1016/j.ejphar.2012.01.030 .

doi: 10.1016/j.ejphar.2012.01.030 pubmed: 22381068 pmcid: 3314091

Wang J, Shanmugam A, Markand S, Zorrilla E, Ganapathy V, Smith SB. Sigma 1 receptor regulates the oxidative stress response in primary retinal Müller glial cells via NRF2 signaling and system xc−, the Na+-independent glutamate–cystine exchanger. Free Radic Biol Med. 2015;86:25–36. https://doi.org/10.1016/j.freeradbiomed.2015.04.009 .

doi: 10.1016/j.freeradbiomed.2015.04.009 pubmed: 25920363 pmcid: 4554890

Prasanth MI, Tencomnao T, Brimson JM. The Sigma-1 receptors role in neuroprotection: Comment on Nrf2 as a therapeutic target in ischemic stroke. Expert Opin Ther Targets. 2021;25(7):613–4. https://doi.org/10.1080/14728222.2021.1948016 .

doi: 10.1080/14728222.2021.1948016 pubmed: 34180350

Brimson JM, Prasanth MI, Isidoro C, Sukprasansap M, Tencomnao T. Cleistocalyx nervosum var. paniala seed extracts exhibit sigma-1 antagonist sensitive neuroprotective effects in PC12 cells and protect C. elegans from stress via the SKN-1/NRF-2 pathway. Nutr Healthy Aging. 2021;6(2):131–46. https://doi.org/10.3233/NHA-200108 .

doi: 10.3233/NHA-200108

Brimson JM, Prasanth MI, Malar DS, Verma K, Plaingam W, Tencomnao T. Bacopa monnieri protects neuronal cell line and Caenorhabditis elegans models of Alzheimer’s disease through sigma-1 receptor antagonist sensitive and antioxidant pathways. Nutr Healthy Aging. 2022;7(3):173–96. https://doi.org/10.3233/NHA-220161 .

doi: 10.3233/NHA-220161

Betzer C, Movius AJ, Shi M, Gai W-P, Zhang J, Jensen PH. Identification of synaptosomal proteins binding to monomeric and oligomeric α-synuclein. PLoS ONE. 2015;10(2):e0116473. https://doi.org/10.1371/journal.pone.0116473 .

doi: 10.1371/journal.pone.0116473 pubmed: 25659148 pmcid: 4319895

Schneider JL, Cuervo AM. Autophagy and human disease: emerging themes. Curr Opin Genet Dev. 2014;26:16–23. https://doi.org/10.1016/j.gde.2014.04.003 .

doi: 10.1016/j.gde.2014.04.003 pubmed: 24907664

Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type α-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem. 2008;283(35):23542–56. https://doi.org/10.1074/jbc.M801992200 .

doi: 10.1074/jbc.M801992200 pubmed: 18566453 pmcid: 2527094

Galvagnion C. The role of lipids interacting with α-synuclein in the pathogenesis of Parkinson’s disease. J Parkinsons Dis. 2017;7(3):433–50. https://doi.org/10.3233/JPD-171103 .

doi: 10.3233/JPD-171103 pubmed: 28671142

Galvagnion C, Brown JW, Ouberai MM, Flagmeier P, Vendruscolo M, Buell AK, et al. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α-synuclein. Proc Natl Acad Sci USA. 2016;113(26):7065–70. https://doi.org/10.1073/pnas.1601899113 .

doi: 10.1073/pnas.1601899113 pubmed: 27298346 pmcid: 4932957

Plotegher N, Berti G, Ferrari E, Tessari I, Zanetti M, Lunelli L, et al. DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Sci Rep. 2017;7:40699. https://doi.org/10.1038/srep40699 .

doi: 10.1038/srep40699 pubmed: 28084443 pmcid: 5233976

Limegrover CS, Yurko R, Izzo NJ, LaBarbera KM, Rehak C, Look G, et al. Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain-derived α-synuclein. J Neurosci Res. 2021;99(4):1161–76. https://doi.org/10.1002/jnr.24782 .

doi: 10.1002/jnr.24782 pubmed: 33480104 pmcid: 7986605

Gold WA, Krishnarajy R, Ellaway C, Christodoulou J. Rett syndrome: a genetic update and clinical review focusing on comorbidities. ACS Chem Neurosci. 2018;9(2):167–76. https://doi.org/10.1021/acschemneuro.7b00346 .

doi: 10.1021/acschemneuro.7b00346 pubmed: 29185709

Vidal S, Xiol C, Pascual-Alonso A, O’Callaghan M, Pineda M, Armstrong J. Genetic landscape of Rett syndrome spectrum: improvements and challenges. Int J Mol Sci. 2019;20(16):3925. https://doi.org/10.3390/ijms20163925 .

doi: 10.3390/ijms20163925 pubmed: 31409060 pmcid: 6719047

Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008;320(5880):1224–9. https://doi.org/10.1126/science.1153252 .

doi: 10.1126/science.1153252 pubmed: 18511691 pmcid: 2443785

Lyst MJ, Bird A. Rett syndrome: a complex disorder with simple roots. Nat Rev Genet. 2015;16(5):261–75. https://doi.org/10.1038/nrg3897 .

doi: 10.1038/nrg3897 pubmed: 25732612

Kriaucionis S, Paterson A, Curtis J, Guy J, Macleod N, Bird A. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol Cell Biol. 2006;26(13):5033–42. https://doi.org/10.1128/mcb.01665-05 .

doi: 10.1128/mcb.01665-05 pubmed: 16782889 pmcid: 1489175

Ricciardi S, Boggio EM, Grosso S, Lonetti G, Forlani G, Stefanelli G, et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet. 2011;20(6):1182–96. https://doi.org/10.1093/hmg/ddq563 .

doi: 10.1093/hmg/ddq563 pubmed: 21212100

Palmer A, Qayumi J, Ronnett G. MeCP2 mutation causes distinguishable phases of acute and chronic defects in synaptogenesis and maintenance, respectively. Mol Cell Neurosci. 2008;37(4):794–807. https://doi.org/10.1016/j.mcn.2008.01.005 .

doi: 10.1016/j.mcn.2008.01.005 pubmed: 18295506

Fonzo M, Sirico F, Corrado B. Evidence-based physical therapy for individuals with Rett syndrome: a systematic review. Brain Sci. 2020;10(7):410. https://doi.org/10.3390/brainsci10070410 .

doi: 10.3390/brainsci10070410 pubmed: 32630125 pmcid: 7407501

Ehinger Y, Matagne V, Villard L, Roux JC. Rett syndrome from bench to bedside: recent advances. F1000Res. 2018;7:398. https://doi.org/10.12688/f1000research.14056.1 .

doi: 10.12688/f1000research.14056.1 pubmed: 29636907 pmcid: 5871944

Chahil G, Bollu PC. Rett Syndrome. In: Aboubakr S, Abu-Ghosh A, Acharya A, Adibi Sedeh P, Aeby T, Aeddula N, Et al. Editors. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023. https://www.ncbi.nlm.nih.gov/books/NBK482252/ .

Ohno K, Saito Y, Ueda R, Togawa M, Ohmae T, Matsuda E, et al. Effect of serotonin 1A agonists and selective serotonin reuptake inhibitors on behavioral and nighttime respiratory symptoms in Rett syndrome. Pediatr Neurol. 2016;60:54-9.e1. https://doi.org/10.1016/j.pediatrneurol.2016.03.016 .

doi: 10.1016/j.pediatrneurol.2016.03.016 pubmed: 27212420

Neul JL, Lane JB, Lee H-S, Geerts S, Barrish JO, Annese F, et al. Developmental delay in Rett syndrome: data from the natural history study. J Neurodev Disord. 2014;6(1):20. https://doi.org/10.1186/1866-1955-6-20 .

doi: 10.1186/1866-1955-6-20 pubmed: 25071871 pmcid: 4112822

Luikenhuis S, Giacometti E, Beard CF, Jaenisch R. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci USA. 2004;101(16):6033–8. https://doi.org/10.1073/pnas.0401626101 .

doi: 10.1073/pnas.0401626101 pubmed: 15069197 pmcid: 395918

Cohen DR, Matarazzo V, Palmer AM, Tu Y, Jeon O-H, Pevsner J, et al. Expression of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs before synaptogenesis. Mol Cell Neurosci. 2003;22(4):417–29. https://doi.org/10.1016/s1044-7431(03)00026-5 .

doi: 10.1016/s1044-7431(03)00026-5 pubmed: 12727440

Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science. 2003;302(5646):885–9. https://doi.org/10.1126/science.1086446 .

doi: 10.1126/science.1086446 pubmed: 14593183

Kikuchi-Utsumi K, Nakaki T. Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus. Neurosci Lett. 2008;440(1):19–22. https://doi.org/10.1016/j.neulet.2008.05.055 .

doi: 10.1016/j.neulet.2008.05.055 pubmed: 18547721

Mysona BA, Zhao J, Smith S, Bollinger KE. Relationship between Sigma-1 receptor and BDNF in the visual system. Exp Eye Res. 2018;167:25–30. https://doi.org/10.1016/j.exer.2017.10.012 .

doi: 10.1016/j.exer.2017.10.012 pubmed: 29031856

Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol. 2013;100:15–29. https://doi.org/10.1016/j.pneurobio.2012.09.001 .

doi: 10.1016/j.pneurobio.2012.09.001 pubmed: 23044468

Nakano M, Osada K, Misonoo A, Fujiwara K, Takahashi M, Ogawa Y, et al. Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells. Life Sci. 2010;86(9–10):309–14. https://doi.org/10.1016/j.lfs.2009.11.017 .

doi: 10.1016/j.lfs.2009.11.017 pubmed: 19995565

Christ MG, Clement AM, Behl C. The sigma-1 receptor at the crossroad of proteostasis, neurodegeneration, and autophagy. Trends Neurosci. 2020;43(2):79–81. https://doi.org/10.1016/j.tins.2019.12.002 .

doi: 10.1016/j.tins.2019.12.002 pubmed: 31918966

Urano F. Wolfram syndrome: diagnosis, management, and treatment. Curr Diab Rep. 2016;16(1):6. https://doi.org/10.1007/s11892-015-0702-6 .

doi: 10.1007/s11892-015-0702-6 pubmed: 26742931 pmcid: 4705145

Abreu D, Urano F. Current landscape of treatments for Wolfram syndrome. Trends Pharmacol Sci. 2019;40(10):711–4. https://doi.org/10.1016/j.tips.2019.07.011 .

doi: 10.1016/j.tips.2019.07.011 pubmed: 31420094 pmcid: 7547529

Delprat B, Maurice T, Delettre C. Wolfram syndrome: MAMs’ connection? Cell Death Dis. 2018;9(3):364. https://doi.org/10.1038/s41419-018-0406-3 .

doi: 10.1038/s41419-018-0406-3 pubmed: 29511163 pmcid: 5840383

Mori T, Hayashi T, Hayashi E, Su TP. Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival. PLoS ONE. 2013;8(10):e76941. https://doi.org/10.1371/journal.pone.0076941 .

doi: 10.1371/journal.pone.0076941 pubmed: 24204710 pmcid: 3799859

Crouzier L, Danese A, Yasui Y, Richard EM, Liévens J-C, Patergnani S, et al. Activation of the sigma-1 receptor chaperone alleviates symptoms of Wolfram syndrome in preclinical models. Sci Transl Med. 2022;14(631):eabh3763. https://doi.org/10.1126/scitranslmed.abh3763 .

doi: 10.1126/scitranslmed.abh3763 pubmed: 35138910 pmcid: 9516885

Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991;206(4):297–300. https://doi.org/10.1016/0922-4106(91)90113-v .

doi: 10.1016/0922-4106(91)90113-v pubmed: 1717296

Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005;25(13):3312–22. https://doi.org/10.1523/jneurosci.4262-04.2005 .

doi: 10.1523/jneurosci.4262-04.2005 pubmed: 15800186 pmcid: 6724906

Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E. Involvement of the sigma1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci. 2004;19(8):2212–20. https://doi.org/10.1111/j.0953-816X.2004.03297.x .

doi: 10.1111/j.0953-816X.2004.03297.x pubmed: 15090047

Abbas H. Expression of sigma receptors in human cancer cell lines and effects of novel sigma-2 ligands on their proliferation [Doctoral Thesis]. In. The University of Wolverhampton open repository. 2018. http://hdl.handle.net/2436/621768 . Accessed 1 Dec 2022.

Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096–9. https://doi.org/10.1212/WNL.0b013e31824e8f0d .

doi: 10.1212/WNL.0b013e31824e8f0d pubmed: 22474298

Chang C, Ramphul K. Amantadine. In: Aboubakr S, Abu-Ghosh A, Acharya A, Adibi Sedeh P, Aeby T, Aeddula N, et al. Editors. StatPearls. Treasure Island (FL): StatPearls Publishing. 2023. https://www.ncbi.nlm.nih.gov/books/NBK499953/ .

Schwab RS, England AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208(7):1168–70.

doi: 10.1001/jama.1969.03160070046011 pubmed: 5818715

Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson’s disease and other movement disorders. Lancet Neurol. 2021;20(12):1048–56. https://doi.org/10.1016/S1474-4422(21)00249-0 .

doi: 10.1016/S1474-4422(21)00249-0 pubmed: 34678171

Kornhuber J, Schoppmeyer K, Riederer P. Affinity of 1-aminoadamantanes for the σ binding site in post-mortem human frontal cortex. Neurosci Lett. 1993;163(2):129–31. https://doi.org/10.1016/0304-3940(93)90362-O .

doi: 10.1016/0304-3940(93)90362-O pubmed: 8309617

Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson’s disease. Cochrane Database Syst Rev. 2003;2003(2):CD003467. https://doi.org/10.1002/14651858.Cd003467 .

doi: 10.1002/14651858.Cd003467 pubmed: 12804468 pmcid: 8715285

Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988;14(1):35–51. https://doi.org/10.2165/00003088-198814010-00003 .

doi: 10.2165/00003088-198814010-00003 pubmed: 3280212

Al-Salama ZT. Amantadine extended release capsules (GOCOVRI) in Parkinson’s disease: a profile of its use in the USA. Drugs Ther Perspect. 2022;38(5):203–14. https://doi.org/10.1007/s40267-022-00912-y .

doi: 10.1007/s40267-022-00912-y

Hauser RA, Mehta SH, Kremens D, et al. Effects of Gocovri (amantadine) extended-release capsules on motor aspects of experiences of daily living in people with Parkinson’s disease and dyskinesia. Neurol Ther. 2021;10(2):739–51. https://doi.org/10.1007/s40120-021-00256-1 .

doi: 10.1007/s40120-021-00256-1 pubmed: 34024025 pmcid: 8571461

Elmer LW, Juncos JL, Singer C, et al. Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson’s disease. CNS Drugs. 2018;32:387–98. https://doi.org/10.1007/s40263-018-0498-4 .

doi: 10.1007/s40263-018-0498-4 pubmed: 29532440 pmcid: 5934466

Isaacson SH, Fahn S, Pahwa R, et al. Parkinson’s patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102. Mov Disord Clin Pract. 2018;5:183–90. https://doi.org/10.1002/mdc3.12595 .

doi: 10.1002/mdc3.12595 pubmed: 29780852 pmcid: 5947645

Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord. 2017;32(12):1701–9. https://doi.org/10.1002/mds.27131 .

doi: 10.1002/mds.27131 pubmed: 28833562 pmcid: 5763269

Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol. 2017;74(8):941–9. https://doi.org/10.1001/jamaneurol.2017.0943 .

doi: 10.1001/jamaneurol.2017.0943 pubmed: 28604926 pmcid: 5710325

Tanner CM, Pahwa R, Hauser RA, Oertel WH, Isaacson SH, Jankovic J, et al. EASE LID 2: a 2-year open-label trial of gocovri (amantadine) extended release for dyskinesia in Parkinson’s disease. J Parkinsons Dis. 2020;10(2):543–58. https://doi.org/10.3233/JPD-191841 .

doi: 10.3233/JPD-191841 pubmed: 31929122 pmcid: 7242830

Rosenberg GA, Appenzeller O. Amantadine, fatigue, and multiple sclerosis. Arch Neurol. 1988;45(10):1104–6. https://doi.org/10.1001/archneur.1988.00520340058012 .

doi: 10.1001/archneur.1988.00520340058012 pubmed: 2972270

Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurol Res. 2012;34(9):854–8. https://doi.org/10.1179/1743132812Y.0000000081 .

doi: 10.1179/1743132812Y.0000000081 pubmed: 22979982

Ledinek AH, Sajko MC, Rot U. Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis–result of a pilot randomized, blind study. Clin Neurol Neurosurg. 2013;115:S86–9. https://doi.org/10.1016/j.clineuro.2013.09.029 .

doi: 10.1016/j.clineuro.2013.09.029 pubmed: 24321164

Khazaei M, Karevan A, Taheri M, Ghafouri-Fard S. Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis. Clin Transl Med. 2019;8(1):20. https://doi.org/10.1186/s40169-019-0239-4 .

doi: 10.1186/s40169-019-0239-4 pubmed: 31263986 pmcid: 6603072

Puca F, Bricolo A, Turella G. Effect of L-dopa or amantadine therapy on sleep spindles in Parkinsonism. Electroencephalogr Clin Neurophysiol. 1973;35(3):327–30. https://doi.org/10.1016/0013-4694(73)90245-9 .

doi: 10.1016/0013-4694(73)90245-9 pubmed: 4126184

Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2021;20(1):38–48. https://doi.org/10.1016/s1474-4422(20)30354-9 .

doi: 10.1016/s1474-4422(20)30354-9 pubmed: 33242419

Villard V, Espallergues J, Keller E, Vamvakides A, Maurice T. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol. 2011;25(8):1101–17. https://doi.org/10.1177/0269881110379286 .

doi: 10.1177/0269881110379286 pubmed: 20829307

Lahmy V, Meunier J, Malmström S, Naert G, Givalois L, Kim SH, et al. Blockade of Tau hyperphosphorylation and Aβ 1–42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ 1 receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2013;38(9):1706. https://doi.org/10.1038/npp.2013.70 .

doi: 10.1038/npp.2013.70 pubmed: 23493042 pmcid: 3717544

Lahmy V, Long R, Morin D, Villard V, Maurice T. Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model. Front Cell Neurosci. 2015;8:463. https://doi.org/10.3389/fncel.2014.00463 .

doi: 10.3389/fncel.2014.00463 pubmed: 25653589 pmcid: 4299448

Voges O, Weigmann I, Bitterlich N, Missling C, Schindler C. A Phase I dose escalation study to investigate safety, tolerability, and pharmacokinetics of ANAVEX 2‐73 in Healthy Male Subjects. Innov Clin Neurosci. 2014;12(Suppl B), 1-20; CNS Summit 2014, Boca Raton, Florida.

Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, et al. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer’s disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. Alzheimers Dement. 2020;6(1):e12013. https://doi.org/10.1002/trc2.12013 .

doi: 10.1002/trc2.12013

Lisak RP, Nedelkoska L, Benjamins JA. Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis. J Neuroimmunol. 2020;342:577188. https://doi.org/10.1016/j.jneuroim.2020.577188 .

doi: 10.1016/j.jneuroim.2020.577188 pubmed: 32179326

Kaufmann WE, Sprouse J, Rebowe N, Hanania T, Klamer D, Missling CU. ANAVEX 2–73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome. Pharmacol Biochem Behav. 2019;187:172796. https://doi.org/10.1016/j.pbb.2019.172796 .

doi: 10.1016/j.pbb.2019.172796 pubmed: 31704481

Reyes ST, Deacon RM, Guo SG, Altimiras FJ, Castillo JB, van der Wildt B, et al. Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy. Sci Rep. 2021;11(1):17150. https://doi.org/10.1038/s41598-021-94079-7 .

doi: 10.1038/s41598-021-94079-7 pubmed: 34433831 pmcid: 8387417

Anavex-Life-Sciences-Corp. ANAVEX2-73 (Blarcamesine) AVATAR phase 3 trial met primary and secondary efficacy endpoints. In: Anavex press release. 2022. https://www.anavex.com/post/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints . Accessed 1 Nov 2022.

Hall H, Iulita MF, Gubert P, Flores Aguilar L, Ducatenzeiler A, Fisher A, et al. AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer’s disease. Alzheimers Dement. 2018;14(6):811–23. https://doi.org/10.1016/j.jalz.2017.11.009 .

doi: 10.1016/j.jalz.2017.11.009 pubmed: 29291374

Anavex-life-Sciences-Corp. Anavex Life Sciences reports positive results from phase 1 clinical trial of ANAVEX3-71. In: Anavex press release. 2022. https://www.anavex.com/post/anavex-life-sciences-reports-positive-results-from-phase-1-clinical-trial-of-anavex-3-71 . Accessed 1 Nov 2022.

Rishton GM, Look GC, Ni ZJ, Zhang J, Wang Y, Huang Y, et al. Discovery of investigational drug CT1812, an antagonist of the Sigma-2 receptor complex for Alzheimer’s disease. ACS Med Chem Lett. 2021;12(9):1389–95. https://doi.org/10.1021/acsmedchemlett.1c00048 .

doi: 10.1021/acsmedchemlett.1c00048 pubmed: 34531947 pmcid: 8436239

Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, et al. Alzheimer’s therapeutics targeting amyloid beta 1–42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS ONE. 2014;9(11):e111899. https://doi.org/10.1371/journal.pone.0111899 .

doi: 10.1371/journal.pone.0111899 pubmed: 25390692 pmcid: 4229119

Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, et al. Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer’s disease modification. Alzheimers Dement. 2021;17(8):1365–82. https://doi.org/10.1371/journal.pone.0111899 .

doi: 10.1371/journal.pone.0111899 pubmed: 33559354 pmcid: 8349378

Harper AR, Nayee S, Topol EJ. Protective alleles and modifier variants in human health and disease. Nat Rev Genet. 2015;16(12):689–701. https://doi.org/10.1038/nrg4017 .

doi: 10.1038/nrg4017 pubmed: 26503796

Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, et al. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer’s disease. Alzheimers Dement. 2019;5:20–6. https://doi.org/10.1016/j.trci.2018.11.001 .

doi: 10.1016/j.trci.2018.11.001

Catalano S, Grundman M, Schneider LS, DeKosky S, Morgan R, Guttendorf R, et al. [P4–567]: a phase 1 safety trial of the Aβ oligomer receptor antagonist CT1812. Alzheimers Dement. 2017;13(7S):P1523–80. https://doi.org/10.1016/j.jalz.2017.07.730 .

doi: 10.1016/j.jalz.2017.07.730

Schwartz AR, Pizon AF, Brooks DE. Dextromethorphan-induced serotonin syndrome. Clin Toxicol. 2008;46(8):771–3. https://doi.org/10.1080/15563650701668625 .

doi: 10.1080/15563650701668625

Shin EJ, Nah SY, Chae JS, Bing G, Shin SW, Yen TP, et al. Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats. Neurochem Int. 2007;50(6):791–9. https://doi.org/10.1016/j.neuint.2007.01.008 .

doi: 10.1016/j.neuint.2007.01.008 pubmed: 17386960

Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1–22. https://doi.org/10.1016/j.pharmthera.2016.01.016 .

doi: 10.1016/j.pharmthera.2016.01.016 pubmed: 26826604

Sauvé WM. Recognizing and treating pseudobulbar affect. CNS Spectr. 2016;21(S1):34–44. https://doi.org/10.1017/S1092852916000791 .

doi: 10.1017/S1092852916000791 pubmed: 28044945

Garnock-Jones KP. Dextromethorphan/quinidine. CNS Drugs. 2011;25(5):435–45. https://doi.org/10.2165/11207260-000000000-00000 .

doi: 10.2165/11207260-000000000-00000 pubmed: 21476614

Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–54. https://doi.org/10.1001/jama.2015.10214 .

doi: 10.1001/jama.2015.10214 pubmed: 26393847

Senanarong V, Cummings J, Fairbanks L, Mega M, Masterman D, O’connor S, et al. Agitation in Alzheimer’s disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord. 2004;17(1–2):14–20. https://doi.org/10.1159/000074080 .

doi: 10.1159/000074080 pubmed: 14560060

O’Gorman C, Jones A, Cummings JL, et al. Efficacy and safety of AXS‐05, a novel, oral, NMDA‐receptor antagonist with multimodal activity, in agitation associated with Alzheimer’s disease: results from ADVANCE‐1, a phase 2/3, double‐blind, active and placebo‐controlled trial: developments in clinical trials and cognitive assessment. Alzheimer Dement. 2020;16:e047684. https://doi.org/10.1002/alz.047684 .

doi: 10.1002/alz.047684

Chou Y-C, Liao J-F, Chang W-Y, Lin M-F, Chen C-F. Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res. 1999;821(2):516–9. https://doi.org/10.1016/s0006-8993(99)01125-7 .

doi: 10.1016/s0006-8993(99)01125-7 pubmed: 10064839

Verhagen Metman L, Del Dotto P, Natté R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson’s disease. Neurology. 1998;51(1):203–6. https://doi.org/10.1212/wnl.51.1.203 .

doi: 10.1212/wnl.51.1.203 pubmed: 9674803

Starr MS, Starr BS, Kaur S. Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson’s disease. Neurosci Biobehav Rev. 1997;21(4):437–46. https://doi.org/10.1016/s0149-7634(96)00039-5 .

doi: 10.1016/s0149-7634(96)00039-5 pubmed: 9195601

Paquette MA, Brudney EG, Putterman DB, Meshul CK, Johnson SW, Berger SP. Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. NeuroReport. 2008;19(1):111–5. https://doi.org/10.1097/WNR.0b013e3282f3b0d1 .

doi: 10.1097/WNR.0b013e3282f3b0d1 pubmed: 18281903 pmcid: 2845294

Liu C-T, Kao L-T, Shih J-H, Chien W-C, Chiu C-H, Ma K-H, et al. The effect of dextromethorphan use in Parkinson’s disease: a 6-hydroxydopamine rat model and population-based study. Eur J Pharmacol. 2019;862:172639. https://doi.org/10.1016/j.ejphar.2019.172639 .

doi: 10.1016/j.ejphar.2019.172639 pubmed: 31491406

Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, et al. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson’s disease. Mov Disord. 2017;32(6):893–903. https://doi.org/10.1002/mds.26976 .

doi: 10.1002/mds.26976 pubmed: 28370447

Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natté R, Chase TN. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord. 1998;13(3):414–7. https://doi.org/10.1002/mds.870130307 .

doi: 10.1002/mds.870130307 pubmed: 9613730

Wilhelm R, Ahl B, Anghelescu I-G. Dextrometorphan-paroxetine, but not dronabinol, effective for treatment-resistant aggression and agitation in an elderly patient with Lewy body dementia. J Clin Psychopharmacol. 2017;37(6):745–7. https://doi.org/10.1097/jcp.0000000000000805 .

doi: 10.1097/jcp.0000000000000805 pubmed: 29035934

Logan BK, Yeakel JK, Goldfogel G, Frost MP, Sandstrom G, Wickham DJ. Dextromethorphan abuse leading to assault, suicide, or homicide. J Forensic Sci. 2012;57(5):1388–94. https://doi.org/10.1111/j.1556-4029.2012.02133.x .

doi: 10.1111/j.1556-4029.2012.02133.x pubmed: 22537430

Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial. Neurotherapeutics. 2017;14(3):762–72. https://doi.org/10.1007/s13311-016-0508-5 .

doi: 10.1007/s13311-016-0508-5 pubmed: 28070747 pmcid: 5509619

Green JR, Allison KM, Cordella C, Richburg BD, Pattee GL, Berry JD, et al. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: a quantitative speech analysis. Br J Clin Pharmacol. 2018;84(12):2849–56. https://doi.org/10.1111/bcp.13745 .

doi: 10.1111/bcp.13745 pubmed: 30152872 pmcid: 6256051

Sancho J, Ferrer S, Burés E, Díaz JL, Torrecilla T, Signes-Costa J, et al. Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis. Respir Med. 2021;186:106536. https://doi.org/10.1016/j.rmed.2021.106536 .

doi: 10.1016/j.rmed.2021.106536 pubmed: 34260979

Chechneva OV, Mayrhofer F, Daugherty DJ, Pleasure DE, Hong J-S, Deng W. Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord. Neurobiol Dis. 2011;44(1):63–72. https://doi.org/10.1016/j.nbd.2011.06.004 .

doi: 10.1016/j.nbd.2011.06.004 pubmed: 21704706 pmcid: 3153572

Lisak RP, Nedelkoska L, Benjamins JA. Effects of dextromethorphan on glial cell function: proliferation, maturation, and protection from cytotoxic molecules. Glia. 2014;62(5):751–62. https://doi.org/10.1002/glia.22639 .

doi: 10.1002/glia.22639 pubmed: 24526455

Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693–702. https://doi.org/10.1002/ana.22093 .

doi: 10.1002/ana.22093 pubmed: 20839238

McGrane I, VandenBerg A, Munjal R. Treatment of pseudobulbar affect with fluoxetine and dextromethorphan in a woman with multiple sclerosis. Ann Pharmacother. 2017;51(11):1035–6. https://doi.org/10.1177/1060028017720746 .

doi: 10.1177/1060028017720746 pubmed: 28691510

Ehde DM, Osborne TL, Jensen MP. Chronic pain in persons with multiple sclerosis. Phys Med Rehabil Clin N Am. 2005;16(2):503–12. https://doi.org/10.1016/j.pmr.2005.01.001 .

doi: 10.1016/j.pmr.2005.01.001 pubmed: 15893684

Merlos M, Romero L, Zamanillo D, Plata-Salamán C, Vela JM. Sigma-1 receptor and pain. Handb Exp Pharmacol. 2017;244:131–61. https://doi.org/10.1007/164_2017_9 .

doi: 10.1007/164_2017_9 pubmed: 28275913

Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59(5):780–7. https://doi.org/10.1002/ana.20828 .

doi: 10.1002/ana.20828 pubmed: 16634036

Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48(5):1212–8. https://doi.org/10.1212/wnl.48.5.1212 .

doi: 10.1212/wnl.48.5.1212 pubmed: 9153445

Abraham RB, Marouani N, Kollender Y, Meller I, Weinbroum AA. Dextromethorphan for phantom pain attenuation in cancer amputees: a double-blind crossover trial involving three patients. Clin J Pain. 2002;18(5):282–5. https://doi.org/10.1097/00002508-200209000-00002 .

doi: 10.1097/00002508-200209000-00002 pubmed: 12218498

Carlsson K, Hoem N, Moberg E, Mathisen L. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand. 2004;48(3):328–36. https://doi.org/10.1111/j.0001-5172.2004.0325.x .

doi: 10.1111/j.0001-5172.2004.0325.x pubmed: 14982566

Gilron I, Booher S, Rowan J, Smoller B, Max M. A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias. Neurology. 2000;55(7):964–71. https://doi.org/10.1212/wnl.55.7.964 .

doi: 10.1212/wnl.55.7.964 pubmed: 11061252

McQuay HJ, Carroll D, Jadad AR, Glynn CJ, Jack T, Moore RA, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain. 1994;59(1):127–33. https://doi.org/10.1016/0304-3959(94)90056-6 .

doi: 10.1016/0304-3959(94)90056-6 pubmed: 7854793

Smith-Hicks CL, Gupta S, Ewen JB, Hong M, Kratz L, Kelley R, Tierney E, Vaurio R, Bibat G, Sanyal A, Yenokyan G, Brereton N, Johnston MV, Naidu S. Randomized open-label trial of dextromethorphan in Rett syndrome. Neurology. 2017;89(16):1684–90. https://doi.org/10.1212/WNL.0000000000004515 .

doi: 10.1212/WNL.0000000000004515 pubmed: 28931647 pmcid: 5644464

Kumagai K, Shono K, Nakayama H, Ohno Y, Sajai I. (2R-trans)-2-butyl-5-heptylpyrrolidine as a potent sigma receptor ligand produced by Streptomyces longispororuber. Journal Antibiot. 2000;53(5):467–73. https://doi.org/10.7164/antibiotics.53.467 .

doi: 10.7164/antibiotics.53.467

Moebius FF, Reiter RJ, Hanner M, Glossmann H. High affinity of sigma1-binding sites for sterol isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol C8–C7 isomerase. Br J Pharmacol. 1997;121(1):1–6. https://doi.org/10.1038/sj.bjp.0701079 .

doi: 10.1038/sj.bjp.0701079 pubmed: 9146879 pmcid: 1564641

Ramachandran S, Chu UB, Mavlyutov TA, Pal A, Pyne S, Ruoho AE. The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. Eur J Pharmacol. 2009;609(1–3):19–26. https://doi.org/10.1016/j.ejphar.2009.03.003 .

doi: 10.1016/j.ejphar.2009.03.003 pubmed: 19285059 pmcid: 3194046

Li J, Satyshur K, Guo LW, Ruoho AE. Sphingoid bases regulate the Sigma-1 receptor—sphingosine and N,N’-dimethylsphingosine are endogenous agonists. Int J Mol Sci. 24(4):3103; Doi: https://doi.org/10.3390/ijms24043103

National-Institute-for-Health-and-Care-Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. In: National Institute for Heath Care Excelence. 2011;TA217:1-77; https://www.nice.org.uk/guidance/ta217 . Accessed 1 Nov 2022.

Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett. 1999;260(1):5–8. https://doi.org/10.1016/S0304-3940(98)00943-4 .

doi: 10.1016/S0304-3940(98)00943-4 pubmed: 10027686

Ramakrishnan NK, Visser AK, Schepers M, Luurtsema G, Nyakas CJ, Elsinga PH, et al. Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with 11 C-SA4503 and microPET. Psychopharmacology. 2014;231(20):3997–4006. https://doi.org/10.1007/s00213-014-3533-2 .

doi: 10.1007/s00213-014-3533-2 pubmed: 24639047

Sato K, Urbano R, Yu C, Yamasaki F, Sato T, Jordan J, et al. The effect of donepezil treatment on cardiovascular mortality. Clin Pharmacol Ther. 2010;88(3):335–8. https://doi.org/10.1038/clpt.2010.98 .

doi: 10.1038/clpt.2010.98 pubmed: 20664535

Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer’s disease. Eur Heart J. 2013;34(33):2585–91. https://doi.org/10.1093/eurheartj/eht182 .

doi: 10.1093/eurheartj/eht182 pubmed: 23735859

Bhuiyan MS, Fukunaga K. Targeting sigma-1 receptor signaling by endogenous ligands for cardioprotection. Expert Opin Ther Targets. 2011;15(2):145–55. https://doi.org/10.1517/14728222.2011.546350 .

doi: 10.1517/14728222.2011.546350 pubmed: 21204730

Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1656–9. https://doi.org/10.1016/j.pnpbp.2008.06.011 .

doi: 10.1016/j.pnpbp.2008.06.011 pubmed: 18647636

Zhang X, Lian S, Zhang Y, Zhao Q. Efficacy and safety of donepezil for mild cognitive impairment: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2022;213:107134. https://doi.org/10.1016/j.clineuro.2022.107134 .

doi: 10.1016/j.clineuro.2022.107134 pubmed: 35078087

Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;6(6):CD001190. https://doi.org/10.1002/14651858.CD001190.pub3 .

doi: 10.1002/14651858.CD001190.pub3 pubmed: 29923184

Wang H, Zong Y, Han Y, Zhao J, Liu H, Liu Y. Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis. Expert Opin Drug Saf. 2022;21(3):407–15. https://doi.org/10.1080/14740338.2022.2027905 .

doi: 10.1080/14740338.2022.2027905 pubmed: 35099343

Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903. https://doi.org/10.1056/NEJMoa1106668 .

doi: 10.1056/NEJMoa1106668 pubmed: 22397651

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590–9.

doi: 10.1111/j.1532-5415.2001.49266.x pubmed: 11843990

Ye CY, Lei Y, Tang XC, Zhang HY. Donepezil attenuates Aβ-associated mitochondrial dysfunction and reduces mitochondrial Aβ accumulation in vivo and in vitro. Neuropharmacology. 2015;95:29–36. https://doi.org/10.1016/j.neuropharm.2015.02.020 .

doi: 10.1016/j.neuropharm.2015.02.020 pubmed: 25744714

Dong H, Yuede CM, Coughlan CA, Murphy KM, Csernansky JG. Effects of donepezil on amyloid-β and synapse density in the Tg2576 mouse model of Alzheimer’s disease. Brain Res. 2009;1303:169–78. https://doi.org/10.1016/j.brainres.2009.09.097 .

doi: 10.1016/j.brainres.2009.09.097 pubmed: 19799879 pmcid: 2789417

Ishibashi K, Miura Y, Wagatsuma K, Ishiwata K, Ishii K. Changes in brain amyloid-β accumulation after donepezil administration. J Clin Neurosci. 2017;45:328–9. https://doi.org/10.1016/j.jocn.2017.08.025 .

doi: 10.1016/j.jocn.2017.08.025 pubmed: 28864409

Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al. Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med. 2007;357(14):1382–92. https://doi.org/10.1056/NEJMoa066583 .

doi: 10.1056/NEJMoa066583 pubmed: 17914039

De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci. 1999;22(12):535–40. https://doi.org/10.1016/s0166-2236(99)01463-0 .

doi: 10.1016/s0166-2236(99)01463-0 pubmed: 10542428

Modell S, Naber D, Holzbach R. Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study. Pharmacopsychiatry. 1996;29(02):63–6. https://doi.org/10.1055/s-2007-979546 .

doi: 10.1055/s-2007-979546 pubmed: 8741023

Hashimoto K, London ED. Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of σ receptors. Eur J Pharmacol. 1995;273(3):307–10. https://doi.org/10.1016/0014-2999(94)00763-w .

doi: 10.1016/0014-2999(94)00763-w pubmed: 7737340

Brooks S, Kaur S, Starr BS, Starr MS. Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson’s disease? J Neural Transm (Vienna). 1996;103(6):737–48. https://doi.org/10.1007/bf01271233 .

doi: 10.1007/bf01271233 pubmed: 8836935

Demerens C, Stankoff B, Zalc B, Lubetzki C. Eliprodil stimulates CNS myelination: new prospects for multiple sclerosis? Neurology. 1999;52(2):346. https://doi.org/10.1212/wnl.52.2.346 .

doi: 10.1212/wnl.52.2.346 pubmed: 9932955

Silkina I, Gan’shina T, Seredin S, Mirzoian R. Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon. E Eksp Klin Farmakol. 2005;68(1):20–4.

Antipova T, Sapozhnikova D, Liu B, Seredenin S. Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons. Eksp Klin Farmakol. 2009;72(1):12–4.

pubmed: 19334503

Cuevas J, Rodriguez A, Behensky A, Katnik C. Afobazole modulates microglial function via activation of both σ-1 and σ-2 receptors. J Pharmacol Exp Ther. 2011;339(1):161–72. https://doi.org/10.1124/jpet.111.182816 .

doi: 10.1124/jpet.111.182816 pubmed: 21715561

Behensky AA, Yasny IE, Shuster AM, Seredenin SB, Petrov AV, Cuevas J. Stimulation of sigma receptors with afobazole blocks activation of microglia and reduces toxicity caused by amyloid-β25–35. J Pharmacol Exp Ther. 2013;347(2):458–67. https://doi.org/10.1124/jpet.113.208348 .

doi: 10.1124/jpet.113.208348 pubmed: 24006337

Behensky AA, Yasny IE, Shuster AM, Seredenin SB, Petrov AV, Cuevas J. Afobazole activation of σ-1 receptors modulates neuronal responses to amyloid-β25–35. J Pharmacol Exp Ther. 2013;347(2):468–77. https://doi.org/10.1124/jpet.113.208330 .

doi: 10.1124/jpet.113.208330 pubmed: 24006338

Martin P, de-Witte PAM, Maurice T, Gammaitoni A, Farfel G, Galer B. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020;105:106989. https://doi.org/10.1016/j.yebeh.2020.106989 .

Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2021;16(4):373–89. https://doi.org/10.1080/17460441.2021.1838483 .

doi: 10.1080/17460441.2021.1838483 pubmed: 33070647

Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554–64. https://doi.org/10.1001/jamaneurol.2022.0829 .

doi: 10.1001/jamaneurol.2022.0829 pubmed: 35499850 pmcid: 9062770

Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243–54. https://doi.org/10.1016/S0140-6736(19)32500-0 .

doi: 10.1016/S0140-6736(19)32500-0 pubmed: 31862249

Specchio N, Pietrafusa N, Doccini V, Trivisano M, Darra F, Ragona F, et al. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a real-world study. Epilepsia. 2020;61(11):2405–14. https://doi.org/10.1111/epi.16690 .

doi: 10.1111/epi.16690 pubmed: 32945537

Chomchoei C, Brimson J, Brimson S. Repurposing fluoxetine to treat lymphocytic leukaemia: apoptosis induction, sigma-1 receptor upregulation, inhibition of IL-2 cytokine production, and autophagy induction. Expert Opin Ther Targets. 2023. https://doi.org/10.1080/14728222.2022.2166829 .

doi: 10.1080/14728222.2022.2166829

Németh ZK, Szûcs A, Vitrai J, Juhász D, Németh JP, Holló A. Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: a retrospective case-control study. Ideggyogy Sz. 2021;74(11–12):389–96. https://doi.org/10.18071/isz.74.0389 .

doi: 10.18071/isz.74.0389 pubmed: 34856085

Emilia M, Rosso D, Laura M, María A. Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug ? Pharmacol Res. 2016;109:101–7. https://doi.org/10.1016/j.phrs.2015.11.021 .

doi: 10.1016/j.phrs.2015.11.021

Safrany ST, Brimson JM. Are fluoxetine’s effects due to sigma-1 receptor agonism? Pharmacol Res. 2016;113:707–8. https://doi.org/10.1016/j.phrs.2016.05.031 .

doi: 10.1016/j.phrs.2016.05.031 pubmed: 27262678

Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, Van Buchem MA, et al. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry. 2008;79(9):1027–31. https://doi.org/10.1136/jnnp.2007.139345 .

doi: 10.1136/jnnp.2007.139345 pubmed: 18450787

Lee JY, Kang SR, Yune TY. Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury. J Neurotrauma. 2015;32(9):633–44. https://doi.org/10.1089/neu.2014.3527 .

doi: 10.1089/neu.2014.3527 pubmed: 25366938 pmcid: 4410451

Sijens PE, Mostert JP, Irwan R, Potze JH, Oudkerk M, De Keyser J. Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Res. 2008;164(3):274–82. https://doi.org/10.1016/j.pscychresns.2007.12.014 .

doi: 10.1016/j.pscychresns.2007.12.014 pubmed: 19017554

Cambron M, Mostert J, D’Hooghe M, Nagels G, Willekens B, Debruyne J, et al. Fluoxetine in progressive multiple sclerosis: the FLUOX-PMS trial. Mult Scler J. 2019;25(13):1728–35. https://doi.org/10.1177/1352458519843051 .

doi: 10.1177/1352458519843051

Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, et al. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open. 2018;8(8):e021944. https://doi.org/10.1136/bmjopen-2018-021944.

De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, et al. Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy Mech Eval. 2020;7(3):1–72. https://doi.org/10.3310/eme07030 .

doi: 10.3310/eme07030

Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, et al. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurol. 2020;19(3):214–25. https://doi.org/10.1016/S1474-4422(19)30485-5 .

doi: 10.1016/S1474-4422(19)30485-5 pubmed: 31981516 pmcid: 7029307

Brimson JM, Prasanth MI, Malar DS, Brimson S, Thitilertdecha P, Tencomnao T. Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: the possible role of the Sigma-1 receptor and autophagy. Expert Opin Ther Targets. 2021;25(6):35–449. https://doi.org/10.1080/14728222.2021.1952987 .

doi: 10.1080/14728222.2021.1952987

Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE. 2008;3(7):e2558. https://doi.org/10.1371/journal.pone.0002558 .

doi: 10.1371/journal.pone.0002558 pubmed: 18596927 pmcid: 2435603

Benedetti F, Campori E, Colombo C, Smeraldi E. Fluvoxamine treatment of major depression associated with multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2004;16(3):364–6. https://doi.org/10.1176/jnp.16.3.364 .

doi: 10.1176/jnp.16.3.364 pubmed: 15377746

Ghareghani M, Zibara K, Sadeghi H, Dokoohaki S, Sadeghi H, Aryanpour R, et al. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. Sci Rep. 2017;7(1):4923. https://doi.org/10.1038/s41598-017-04968-z .

doi: 10.1038/s41598-017-04968-z pubmed: 28687730 pmcid: 5501834

Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR. Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol. 2012;22(4):308–17. https://doi.org/10.1016/j.euroneuro.2011.08.002 .

doi: 10.1016/j.euroneuro.2011.08.002 pubmed: 21911285

Nikiforuk A, Popik P. Ketamine prevents stress-induced cognitive inflexibility in rats. Psychoneuroendocrinology. 2014;40:119–22. https://doi.org/10.1016/j.psyneuen.2013.11.009 .

doi: 10.1016/j.psyneuen.2013.11.009 pubmed: 24485483

Shibakawa YS, Sasaki Y, Goshima Y, Echigo N, Kamiya Y, Kurahashi K, et al. Effects of ketamine and propofol on inflammatory responses of primary glial cell cultures stimulated with lipopolysaccharide. Br J Anaesth. 2005;95(6):803–10. https://doi.org/10.1093/bja/aei256 .

doi: 10.1093/bja/aei256 pubmed: 16227338

Hollinger A, Rüst CA, Riegger H, Gysi B, Tran F, Brügger J, et al. Ketamine vs haloperidol for prevention of cognitive dysfunction and postoperative delirium: a phase IV multicentre randomised placebo-controlled double-blind clinical trial. J Clin Anesth. 2021;68:110099. https://doi.org/10.1016/j.jclinane.2020.110099 .

doi: 10.1016/j.jclinane.2020.110099 pubmed: 33120302

Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 2013;16(9):2111–7. https://doi.org/10.1017/S1461145713000485 .

doi: 10.1017/S1461145713000485 pubmed: 23683309

Zhang MW, Ho RC. Controversies of the effect of ketamine on cognition. Front Psychiatry. 2016;7:47. https://doi.org/10.3389/fpsyt.2016.00047 .

doi: 10.3389/fpsyt.2016.00047 pubmed: 27065891 pmcid: 4809869

Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63(5):530–8. https://doi.org/10.1001/archpsyc.63.5.530 .

doi: 10.1001/archpsyc.63.5.530 pubmed: 16651510 pmcid: 3530614

Aan Het Rot M, Zarate CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72(7):537–47. https://doi.org/10.1016/j.biopsych.2012.05.003.

Rocha FL, de Vasconcelos Cunha UG, Paschoalin RC, Hara C, Thomaz DP. Use of subcutaneous ketamine to rapidly improve severe treatment-resistant depression in a patient with Alzheimer’s disease. Int Clin Psychopharmacol. 2021;36(2):104–5. https://doi.org/10.1097/YIC.0000000000000334 .

doi: 10.1097/YIC.0000000000000334 pubmed: 33230024

He Y, Li H, Huang J, Huang S, Bai Y, Li Y, et al. Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: a systematic review and network meta-analysis. J Psychopharmacol. 2021;35(8):901–9. https://doi.org/10.1177/02698811211030181 .

doi: 10.1177/02698811211030181 pubmed: 34238048

Yeung L, Wai MS, Fan M, Mak Y, Lam W, Li Z, et al. Hyperphosphorylated tau in the brains of mice and monkeys with long-term administration of ketamine. Toxicol Lett. 2010;193(2):189–93. https://doi.org/10.1016/j.toxlet.2010.01.008 .

doi: 10.1016/j.toxlet.2010.01.008 pubmed: 20093173

Ferro M, Angelucci M, Anselmo-Franci J, Canteras N, Da Cunha C. Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson’s disease. Braz J Med Biol Res. 2007;40:89–96. https://doi.org/10.1590/s0100-879x2007000100012 .

doi: 10.1590/s0100-879x2007000100012 pubmed: 17225001

Vecchia DD, Kanazawa LKS, Wendler E, Hocayen PdAS, Vital MABF, Takahashi RN, et al. Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson’s disease. Brain Res Bull. 2021;168:63–73. https://doi.org/10.1016/j.brainresbull.2020.12.011.

Fan J-C, Song J-J, Wang Y, Chen Y, Hong D-X. Neuron-protective effect of subanesthestic-dosage ketamine on mice of Parkinson’s disease. Asian Pac J Trop Med. 2017;10(10):1007–10. https://doi.org/10.1016/j.apjtm.2017.09.014 .

doi: 10.1016/j.apjtm.2017.09.014 pubmed: 29111184

Wright JJ, Goodnight PD, McEvoy MD. The utility of ketamine for the preoperative management of a patient with Parkinson’s disease. Anesth Analg. 2009;108(3):980–2. https://doi.org/10.1213/ane.0b013e3181924025 .

doi: 10.1213/ane.0b013e3181924025 pubmed: 19224812

Salazar G, Motamed C. A remifentanil/ketamine sedation in surgical cancer patients having severe Parkinson’s disease: two case reports. J Opioid Manag. 2012;8(2):133–4. https://doi.org/10.5055/jom.2012.0106 .

doi: 10.5055/jom.2012.0106 pubmed: 22616319

Barenboim I, Lafer B. Maintenance use of ketamine for treatment-resistant depression: an open-label pilot study. Braz J Psychiatry. 2018;40(1):110. https://doi.org/10.1590/1516-4446-2017-2380 .

doi: 10.1590/1516-4446-2017-2380 pubmed: 29590266 pmcid: 6899427

Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, et al. Ketamine for treatment-resistant unipolar depression. CNS Drugs. 2012;26(3):189–204. https://doi.org/10.2165/11599770-000000000-00000 .

doi: 10.2165/11599770-000000000-00000 pubmed: 22303887 pmcid: 3677048

Feifel D. Breaking sad: unleashing the breakthrough potential of k etamine’s rapid antidepressant effects. Drug Dev Res. 2016;77(8):489–94. https://doi.org/10.1002/ddr.21347 .

doi: 10.1002/ddr.21347 pubmed: 27888525

Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2014;155:123–9. https://doi.org/10.1016/j.jad.2013.10.036 .

doi: 10.1016/j.jad.2013.10.036 pubmed: 24268616

Wang X, Chang L, Tan Y, Qu Y, Shan J, Hashimoto K. (R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice. Brain Res Bull. 2021;177:316–23. https://doi.org/10.1016/j.brainresbull.2021.10.013 .

doi: 10.1016/j.brainresbull.2021.10.013 pubmed: 34688833

Wang X, Chang L, Wan X, Tan Y, Qu Y, Shan J, et al. (R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: a role of gut–microbiota–brain axis. Neurobiol Dis. 2022;165:105635. https://doi.org/10.1016/j.nbd.2022.105635 .

doi: 10.1016/j.nbd.2022.105635 pubmed: 35085752

Sakai T, Tomiyasu S, Ono T, Yamada H, Sumikawa K. Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine. Clin J Pain. 2004;20(5):375–6. https://doi.org/10.1097/00002508-200409000-00016 .

doi: 10.1097/00002508-200409000-00016 pubmed: 15322448

Messer MM, Haller IV. Ketamine therapy for treatment-resistant depression in a patient with multiple sclerosis: a case report. Innov Clin Neurosci. 2017;14(1–2):56–9.

pubmed: 28386522 pmcid: 5373796

Patrizi A, Picard N, Simon AJ, Gunner G, Centofante E, Andrews NA, et al. Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves Rett syndrome phenotype. Biol Psychiatry. 2016;79(9):755–64. https://doi.org/10.1016/j.biopsych.2015.08.018 .

doi: 10.1016/j.biopsych.2015.08.018 pubmed: 26410354

Kron M, Howell CJ, Adams IT, Ransbottom M, Christian D, Ogier M, et al. Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment. J Neurosci. 2012;32(40):13860–72. https://doi.org/10.1523/jneurosci.2159-12.2012 .

doi: 10.1523/jneurosci.2159-12.2012 pubmed: 23035095 pmcid: 3500840

Jolly T, McLean HS. Use of ketamine during procedural sedation: indications, controversies, and side effects. J Infus Nurs. 2012;35(6):377–82. https://doi.org/10.1097/NAN.0b013e31827068c1 .

doi: 10.1097/NAN.0b013e31827068c1 pubmed: 23132086

Mount C, Downton C. Alzheimer disease: progress or profit? Nat Med. 2006;12(7):780–4. https://doi.org/10.1038/nm0706-780 .

doi: 10.1038/nm0706-780 pubmed: 16829947

Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Memantine, donepezil, or combination therapy—what is the best therapy for Alzheimer’s disease? A network meta-analysis. Brain Behav. 2020;10(11):e01831. https://doi.org/10.1002/brb3.1831 .

doi: 10.1002/brb3.1831 pubmed: 32914577 pmcid: 7667299

Schmitt HP. On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease. Med Hypotheses. 2005;65(2):259–65. https://doi.org/10.1016/j.mehy.2005.03.011 .

doi: 10.1016/j.mehy.2005.03.011 pubmed: 15922097

Parsons C, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data. Neuropharmacol. 1999;38(6):735–67. https://doi.org/10.1016/s0028-3908(99)00019-2 .

doi: 10.1016/s0028-3908(99)00019-2

Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 2003;9(3):275–308. https://doi.org/10.1111/j.1527-3458.2003.tb00254.x .

doi: 10.1111/j.1527-3458.2003.tb00254.x pubmed: 14530799 pmcid: 6741669

Martina M, Turcotte MEB, Halman S, Bergeron R. The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J Physiol. 2007;578(1):143–57. https://doi.org/10.1113/jphysiol.2006.116178 .

doi: 10.1113/jphysiol.2006.116178 pubmed: 17068104

Chaki S, Okuyama S, Ogawa S-i, Tomisawa K. Regulation of NMDA-induced [3H] dopamine release from rat hippocampal slices through sigma-1 binding sites. Neurochem Int. 1998;33(1):29–34. https://doi.org/10.1113/jphysiol.2006.116178.

Sha S, Qu WJ, Li L, Lu ZH, Chen L, Yu WF, et al. Sigma-1 receptor knockout impairs neurogenesis in dentate gyrus of adult hippocampus via down-regulation of NMDA receptors. CNS Neurosci Ther. 2013;19(9):705–13. https://doi.org/10.1111/cns.12129 .

doi: 10.1111/cns.12129 pubmed: 23745740 pmcid: 6493366

Pabba M, Wong AY, Ahlskog N, Hristova E, Biscaro D, Nassrallah W, et al. NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus. J Neurosci. 2014;34(34):11325–38. https://doi.org/10.1523/JNEUROSCI.0458-14.2014 .

doi: 10.1523/JNEUROSCI.0458-14.2014 pubmed: 25143613 pmcid: 6615506

Stahl SM. Mechanism of action of ketamine. CNS Spectr. 2013;18(4):171–4. https://doi.org/10.1017/S109285291300045X .

doi: 10.1017/S109285291300045X pubmed: 23866089

Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20–7. https://doi.org/10.1159/000102568 .

doi: 10.1159/000102568 pubmed: 17496417

Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):6. https://doi.org/10.1186/alzrt160 .

doi: 10.1186/alzrt160 pubmed: 23336974 pmcid: 3580327

Schmitt FA, van Dyck CH, Wichems CH, Olin JT, Group MM-M-S. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord. 2006;20(4):255–62. https://doi.org/10.1097/01.wad.0000213860.35355.d4 .

Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600–7. https://doi.org/10.1136/jnnp.2008.158964 .

doi: 10.1136/jnnp.2008.158964 pubmed: 19204022

Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24. https://doi.org/10.1001/jama.291.3.317 .

doi: 10.1001/jama.291.3.317 pubmed: 14734594

Hendrix S, Ellison N, Stanworth S, Otcheretko V, Tariot PN. Post Hoc Evidence for an additive effect of memantine and donepezil: consistent findings from DOMINO-AD Study and Memantine Clinical Trial Program. J Prev Alzheimers Dis. 2015;2(3):165–71. https://doi.org/10.14283/jpad.2015.66 .

doi: 10.14283/jpad.2015.66 pubmed: 29226942

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83–9. https://doi.org/10.2174/156720508783884576 .

doi: 10.2174/156720508783884576 pubmed: 18288936

Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord. 2009;24(8):1217–21. https://doi.org/10.1002/mds.22495 .

doi: 10.1002/mds.22495 pubmed: 19370737

Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77. https://doi.org/10.1016/S1474-4422(10)70194-0 .

doi: 10.1016/S1474-4422(10)70194-0 pubmed: 20729148

Ondo WG, Shinawi L, Davidson A, et al. Memantine for non-motor features of Parkinson’s disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord. 2011;17(3):156–9. https://doi.org/10.1016/j.parkreldis.2010.12.003 .

doi: 10.1016/j.parkreldis.2010.12.003 pubmed: 21193343

Moreau C, Delval A, Tiffreau V, et al. Memantine for axial signs in Parkinson’s disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry. 2013;84(5):552–5. https://doi.org/10.1136/jnnp-2012-303182 .

doi: 10.1136/jnnp-2012-303182 pubmed: 23077087

Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135–43. https://doi.org/10.1136/jnnp-2014-307659 .

doi: 10.1136/jnnp-2014-307659 pubmed: 24828899

Sanjay M, Amir G, John R, Scott O, Stephen D, et al. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. Clin Ther. 2008;30:9. https://doi.org/10.1016/j.clinthera.2008.09.006 .

doi: 10.1016/j.clinthera.2008.09.006

Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC Jr, et al. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008;28(2):235–9. https://doi.org/10.1097/JCP.0b013e31816774de .

doi: 10.1097/JCP.0b013e31816774de pubmed: 18344738

PRX-00023 Therapy in localization-related epilepsy. In: NIH U.S. National Library of Medicine clinical trials web site; 2011. https://clinicaltrials.gov/ct2/show/NCT01281956. Accessed 1 Dec 2022.

Merritt HH, Putnam TJ. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. J Am Med Assoc. 1938;111(12):1068–73. https://doi.org/10.1001/jama.1938.02790380010004 .

doi: 10.1001/jama.1938.02790380010004

Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5(7):553–64. https://doi.org/10.1038/nrn1430 .

doi: 10.1038/nrn1430 pubmed: 15208697

Tchedre KT, Huang RQ, Dibas A, Krishnamoorthy RR, Dillon GH, Yorio T. Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction. Invest Ophthalmol Vis Sci. 2008;49(11):4993–5002. https://doi.org/10.1167/iovs.08-1867 .

doi: 10.1167/iovs.08-1867 pubmed: 18641291

Mueller BH II, Park Y, Daudt DR III, Ma H-Y, Akopova I, Stankowska DL, et al. Sigma-1 receptor stimulation attenuates calcium influx through activated L-type voltage gated calcium channels in purified retinal ganglion cells. Exp Eye Res. 2013;107:21–31. https://doi.org/10.1016/j.exer.2012.11.002 .

doi: 10.1016/j.exer.2012.11.002 pubmed: 23183135

Zhang K, Zhao Z, Lan L, Wei X, Wang L, Liu X, et al. Sigma-1 receptor plays a negative modulation on N-type calcium channel. Front Pharmacol. 2017;8:302. https://doi.org/10.3389/fphar.2017.00302 .

doi: 10.3389/fphar.2017.00302 pubmed: 28603497 pmcid: 5445107

Zhang H, Cuevas J. Sigma receptors inhibit high-voltage–activated calcium channels in rat sympathetic and parasympathetic neurons. J Neurophysiol. 2002;87(6):2867–79. https://doi.org/10.1152/jn.2002.87.6.2867 .

doi: 10.1152/jn.2002.87.6.2867 pubmed: 12037190

DeHaven-Hudkins D, Ford-Rice F, Allen J, Hudkins R. Allosteric modulation of ligand binding to [3H](+) pentazocine-defined σ recognition sites by phenytoin. Life Sci. 1993;53(1):41–8. https://doi.org/10.1016/0024-3205(93)90609-7 .

doi: 10.1016/0024-3205(93)90609-7 pubmed: 8515681

Braakman HM, Verhoeven JS, Erasmus CE, Haaxma CA, Willemsen MH, Schelhaas HJ. Phenytoin as a last-resort treatment in SCN 8A encephalopathy. Epilepsia Open. 2017;2(3):343–4. https://doi.org/10.1002/epi4.12059 .

doi: 10.1002/epi4.12059 pubmed: 29588963 pmcid: 5862112

Dilena R, Striano P, Gennaro E, Bassi L, Olivotto S, Tadini L, et al. Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy. Brain Dev. 2017;39(4):345–8. https://doi.org/10.1016/j.braindev.2016.10.015 .

doi: 10.1016/j.braindev.2016.10.015 pubmed: 27876397

Su TP, Wu XZ, Cone EJ, Shukla K, Gund TM, Dodge AL, et al. Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand. J Pharmacol Exp Ther. 1991;259(2):543–50.

pubmed: 1658302

Motawe ZY, Abdelmaboud SS, Cuevas J, Breslin JW. PRE-084 as a tool to uncover potential therapeutic applications for selective sigma-1 receptor activation. Int J Biochem Cell Biol. 2020;126:105803; Doi: https://doi.org/10.1016/j.biocel.2020.105803

Motawe ZY, Farsaei F, Abdelmaboud SS, Cuevas J, Breslin JW. Sigma-1 receptor activation-induced glycolytic ATP production and endothelial barrier enhancement. Microcirculation. 2020;27(6):e12620. https://doi.org/10.1111/micc.12620 .

doi: 10.1111/micc.12620 pubmed: 32279379 pmcid: 7821090

An Y, Qi Y, Li Y, Li Z, Yang C, Jia D. Activation of the sigma-1 receptor attenuates blood–brain barrier disruption by inhibiting amyloid deposition in Alzheimer’s disease mice. Neurosci Lett. 2022;774:136528. https://doi.org/10.1016/j.neulet.2022.136528 .

doi: 10.1016/j.neulet.2022.136528 pubmed: 35157973

Penas C, Pascual-Font A, Mancuso R, Forés J, Casas C, Navarro X. Sigma receptor agonist 2-(4-morpholinethyl) 1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury. J Neurotrauma. 2011;28(5):831–40. https://doi.org/10.1089/neu.2010.1674 .

doi: 10.1089/neu.2010.1674 pubmed: 21332255

Francardo V, Bez F, Wieloch T, Nissbrandt H, Ruscher K, Cenci MA. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain. 2014;137(7):1998–2014. https://doi.org/10.1093/brain/awu107 .

doi: 10.1093/brain/awu107 pubmed: 24755275

Rao YL, Ganaraja B, Murlimanju BV, Joy T, Krishnamurthy A, Agrawal A. Hippocampus and its involvement in Alzheimer’s disease: a review. 3 Biotech. 2022;12(2):55; Doi: https://doi.org/10.1007/s13205-022-03123-4

Eriksson PS, Perfilieva E, Björk-Eriksson T, Alborn A-M, Nordborg C, Peterson DA, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4(11):1313–7. https://doi.org/10.1038/3305 .

doi: 10.1038/3305 pubmed: 9809557

Borbély E, Varga V, Szögi T, Schuster I, Bozsó Z, Penke B, et al. Impact of two neuronal Sigma-1 receptor modulators, PRE084 and DMT, on neurogenesis and neuroinflammation in an Aβ1–42-injected, wild-type mouse model of AD. Int J Mol Sci. 2022;23(5):2514. https://doi.org/10.3390/ijms23052514 .

doi: 10.3390/ijms23052514 pubmed: 35269657 pmcid: 8910266

Li L, Xu B, Zhu Y, Chen L, Sokabe M, Chen L. DHEA prevents Aβ25–35-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling. Neuropharmacol. 2010;59(4–5):323–33. https://doi.org/10.1016/j.neuropharm.2010.02.009 .

doi: 10.1016/j.neuropharm.2010.02.009

Estévez-Silva HM, Cuesto G, Romero N, Brito-Armas JM, Acevedo-Arozena A, Acebes Á, et al. Pridopidine promotes synaptogenesis and reduces spatial memory deficits in the Alzheimer’s disease APP/PS1 mouse model. Neurotherapeutics. 2022;19(5):1566–87. https://doi.org/10.1007/s13311-022-01280-1 .

doi: 10.1007/s13311-022-01280-1 pubmed: 35917088 pmcid: 9606189

Guzmán-Lenis MS, Navarro X, Casas C. Selective sigma receptor agonist 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons. Neuroscience. 2009;162(1):31–8. https://doi.org/10.1016/j.neuroscience.2009.03.067 .

doi: 10.1016/j.neuroscience.2009.03.067 pubmed: 19345724

Mancuso R, Oliván S, Rando A, Casas C, Osta R, Navarro X. Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics. 2012;9(4):814–26. https://doi.org/10.1007/s13311-012-0140-y .

doi: 10.1007/s13311-012-0140-y pubmed: 22935988 pmcid: 3480575

Mancuso R, Del Valle J, Morell M, Pallás M, Osta R, Navarro X. Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity? Orphanet J Rare Dis. 2014;9(1):1–11. https://doi.org/10.1186/1750-1172-9-78 .

doi: 10.1186/1750-1172-9-78

Gaja-Capdevila N, Hernández N, Navarro X, Herrando-Grabulosa M. Sigma-1 receptor is a pharmacological target to promote neuroprotection in the SOD1G93A ALS mice. Front Pharmacol. 2021;12:780588. https://doi.org/10.3389/fphar.2021.780588 .

doi: 10.3389/fphar.2021.780588 pubmed: 34955848 pmcid: 8702863

Peviani M, Salvaneschi E, Bontempi L, Petese A, Manzo A, Rossi D, et al. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiol Dis. 2014;62:218–32. https://doi.org/10.1016/j.nbd.2013.10.010 .

doi: 10.1016/j.nbd.2013.10.010 pubmed: 24141020

Barwick SR, Siddiq MS, Wang J, Xiao H, Marshall B, Perry E, et al. Sigma 1 receptor co-localizes with NRF2 in retinal photoreceptor cells. Antioxidants. 2021;10(6):981. https://doi.org/10.3390/antiox10060981 .

doi: 10.3390/antiox10060981 pubmed: 34205384 pmcid: 8234060

Weng TY, Hung DT, Su TP, Tsai SYA. Loss of Sigma-1 receptor chaperone promotes astrocytosis and enhances the Nrf2 antioxidant defense. Oxid Med Cell Longev. 2017;2017:4582135. https://doi.org/10.1155/2017/4582135 .

doi: 10.1155/2017/4582135 pubmed: 28883901 pmcid: 5573104

Lasbleiz C, Peyrel A, Tarot P, Sarniguet J, Crouzier L, Cubedo N, et al. Sigma-1 receptor agonist PRE-084 confers protection against TAR DNA-binding protein-43 toxicity through NRF2 signalling. Redox Biol. 2022;58:102542. https://doi.org/10.1016/j.redox.2022.102542 .

doi: 10.1016/j.redox.2022.102542 pubmed: 36442393 pmcid: 9706169

Hyrskyluoto A, Pulli I, Törnqvist K, Ho H, Korhonen L, Lindholm D. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway. Cell Death Dis. 2013;4(5):e646. https://doi.org/10.1038/cddis.2013.170 .

doi: 10.1038/cddis.2013.170 pubmed: 23703391 pmcid: 3674377

Bol’Shakova A, Kraskovskaya N, Gainullina A, Kukanova E, Vlasova O, Bezprozvanny I. Neuroprotective effect of σ1-receptors on the cell model of Huntington’s disease. Bull Exp Biol Med. 2017;164:252–8. https://doi.org/10.1007/s10517-017-3968-7 .

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, et al. Pridopidine, a clinic-ready compound, reduces 3, 4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Mov Disord. 2019;34(5):708–16. https://doi.org/10.1002/mds.27565 .

doi: 10.1002/mds.27565 pubmed: 30575996

Grachev ID, Meyer PM, Becker GA, Bronzel M, Marsteller D, Pastino G, et al. Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study. Eur J Nucl Med Mol Imaging. 2021;48(4):1103–15. https://doi.org/10.1007/s00259-020-05030-3 .

doi: 10.1007/s00259-020-05030-3 pubmed: 32995944

Sahlholm K, Sijbesma JWA, Maas B, Kwizera C, Marcellino D, Ramakrishnan NK, et al. Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology. 2015;232(18):3443–53. https://doi.org/10.1007/s00213-015-3997-8 .

doi: 10.1007/s00213-015-3997-8 pubmed: 26159455 pmcid: 4537502

Bourne J, Harris KM. Do thin spines learn to be mushroom spines that remember? Curr Opin Neurobiol. 2007;17(3):381–6. https://doi.org/10.1016/j.conb.2007.04.009 .

doi: 10.1016/j.conb.2007.04.009 pubmed: 17498943

Bourne JN, Harris KM. Balancing structure and function at hippocampal dendritic spines. Annu Rev Neurosci. 2008;31:47–67. https://doi.org/10.1146/annurev.neuro.31.060407.125646 .

doi: 10.1146/annurev.neuro.31.060407.125646 pubmed: 18284372 pmcid: 2561948

Hayashi-Takagi A, Yagishita S, Nakamura M, Shirai F, Wu YI, Loshbaugh AL, et al. Labelling and optical erasure of synaptic memory traces in the motor cortex. Nature. 2015;525(7569):333–8. https://doi.org/10.1038/nature15257 .

doi: 10.1038/nature15257 pubmed: 26352471 pmcid: 4634641

Ionescu A, Gradus T, Altman T, Maimon R, Avraham NS, Geva M, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model. Cell Death Dis. 2019;10(3):210. https://doi.org/10.1038/s41419-019-1451-2 .

doi: 10.1038/s41419-019-1451-2 pubmed: 30824685 pmcid: 6397200

Estévez-Silva HM, Mediavilla T, Giacobbo BL, Liu X, Sultan FR, Marcellino DJ. Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis. Eur J Neurosci. 2022;55(5):1356–72. https://doi.org/10.1111/ejn.15608 .

doi: 10.1111/ejn.15608 pubmed: 35080077 pmcid: 9305776

Wang S-M, Wu H-E, Yasui Y, Geva M, Hayden M, Maurice T, et al. Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine. Autophagy. 2023;19(1):126–51. https://doi.org/10.1080/15548627.2022.2063003 .

doi: 10.1080/15548627.2022.2063003 pubmed: 35507432

Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, et al. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI insight. 2017;2:23. https://doi.org/10.1172/jci.insight.95665 .

doi: 10.1172/jci.insight.95665

Nguyen KQ, Rymar VV, Sadikot AF. Impaired TrkB signaling underlies reduced BDNF-mediated trophic support of striatal neurons in the R6/2 mouse model of Huntington’s disease. Front Cell Neurosci. 2016;10:37. https://doi.org/10.3389/fncel.2016.00037 .

doi: 10.3389/fncel.2016.00037 pubmed: 27013968 pmcid: 4783409

Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, et al. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Mol Neurodegener. 2018;13(1):25. https://doi.org/10.1186/s13024-018-0259-3 .

doi: 10.1186/s13024-018-0259-3 pubmed: 29783994 pmcid: 5963017

Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington’s disease phenotypes in YAC128 mice. J Neurosci. 2010;30(44):14708–18. https://doi.org/10.1523/JNEUROSCI.1637-10.2010 .

doi: 10.1523/JNEUROSCI.1637-10.2010 pubmed: 21048129 pmcid: 2989389

Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, et al. Pridopidine activates neuroprotective pathways impaired in Huntington disease. Hum Mol Genet. 2016;25(18):3975–87. https://doi.org/10.1093/hmg/ddw238 .

doi: 10.1093/hmg/ddw238 pubmed: 27466197 pmcid: 5291233

Yagasaki Y, Numakawa T, Kumamaru E, Hayashi T, Su TP, Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J Biol Chem. 2006;281(18):12941–9. https://doi.org/10.1074/jbc.M508157200 .

doi: 10.1074/jbc.M508157200 pubmed: 16522641

Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease. Mov Disord. 2013;28(10):1407–15. https://doi.org/10.1002/mds.25362 .

doi: 10.1002/mds.25362

De Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, et al. Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(12):1049–57. https://doi.org/10.1016/S1474-4422(11)70233-2 .

doi: 10.1016/S1474-4422(11)70233-2 pubmed: 22071279

Reilmann R, McGarry A, Grachev ID, Savola J-M, Borowsky B, Eyal E, et al. Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18(2):165–76. https://doi.org/10.1016/S1474-4422(18)30391-0 .

doi: 10.1016/S1474-4422(18)30391-0 pubmed: 30563778

McGarry A, Auinger P, Kieburtz K, Geva M, Mehra M, Abler V, et al. Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease. J Huntingtons Dis. 2020;9(2):173–84. https://doi.org/10.3233/JHD-190393 .

doi: 10.3233/JHD-190393 pubmed: 32508327

Ponten H, Kullingsjö J, Sonesson C, Waters S, Waters N, Tedroff J. The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model. Eur J Pharmacol. 2013;698(1–3):278–85. https://doi.org/10.1016/j.ejphar.2012.10.039 .

doi: 10.1016/j.ejphar.2012.10.039 pubmed: 23127496

McFarthing K, Prakash N, Simuni T. Clinical trial highlights – dyskinesia. J Parkinsons Dis. 2019;9:449–65. https://doi.org/10.3233/JPD-199002 .

doi: 10.3233/JPD-199002 pubmed: 31356217 pmcid: 6704371

Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson’s disease: a feature inherent to the treatment or the disease? Prog Neurobiol. 2009;87(1):1–9. https://doi.org/10.1016/j.pneurobio.2008.09.013 .

doi: 10.1016/j.pneurobio.2008.09.013 pubmed: 18938208

Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine. Ther Adv Drug Saf. 2018;9(3):171–8. https://doi.org/10.1177/2042098617750555 .

doi: 10.1177/2042098617750555 pubmed: 29492246 pmcid: 5810854

Terada K, Migita K, Matsushima Y, Sugimoto Y, Kamei C, Matsumoto T, et al. Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. PLoS ONE. 2018;13(12):e0209250. https://doi.org/10.1371/journal.pone.0209250 .

doi: 10.1371/journal.pone.0209250 pubmed: 30557385 pmcid: 6296549

Corey-Bloom J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psyopharmacol. 1998;1:55–65.

Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ. 1999;318(7184):633–8. https://doi.org/10.1136/bmj.318.7184.633 .

doi: 10.1136/bmj.318.7184.633 pubmed: 10066203 pmcid: 27767

Finkel SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer’s disease. Clin Ther. 2004;26(7):980–90. https://doi.org/10.1016/s0149-2918(04)90172-5 .

doi: 10.1016/s0149-2918(04)90172-5 pubmed: 15336465

Yi B, Sahn JJ, Ardestani PM, Evans AK, Scott LL, Chan JZ, et al. Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer’s disease. J Neurochem. 2017;140(4):561–75. https://doi.org/10.1111/jnc.13917 .

doi: 10.1111/jnc.13917 pubmed: 27926996 pmcid: 5312682

Yano T, Tanabe H, Kobayashi K, Kobayashi H, Nabetani A, Sakai Y, et al. Sigma-1 receptor is a molecular target for novel neuroprotectant T-817MA. Alzheimer Dement. 2015;11(7):P861. https://doi.org/10.1016/j.jalz.2015.08.038 .

doi: 10.1016/j.jalz.2015.08.038

Nguyen PTH, Kimura T, Ho SA, Tran AH, Ono T, Nishijo H. Ameliorative effects of a neuroprotective agent, T-817MA, on place learning deficits induced by continuous infusion of amyloid-β peptide (1–40) in rats. Hippocampus. 2007;17(6):443–55. https://doi.org/10.1002/hipo.20281 .

doi: 10.1002/hipo.20281 pubmed: 17397046

Kimura T, Hong Nguyen PT, Ho SA, Tran AH, Ono T, Nishijo H. T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused icv with amyloid-β peptide. Br J Pharmacol. 2009;157(3):451–63. https://doi.org/10.1111/j.1476-5381.2009.00141.x .

doi: 10.1111/j.1476-5381.2009.00141.x pubmed: 19371351 pmcid: 2707991

Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, et al. Safety and efficacy of edonerpic maleate for patients with mild to moderate alzheimer disease: a phase 2 randomized clinical trial. JAMA Neurol. 2019;76(11):1330–9. https://doi.org/10.1001/jamaneurol.2019.1868 .

doi: 10.1001/jamaneurol.2019.1868 pubmed: 31282954 pmcid: 6618817

Schneider L, Porsteinsson A, Farlow M, Shimakura A, Nakagawa M, Iwakami N. The neuroprotective and neurotrophic agent T-817MA for Alzheimer’s disease: randomized, double-blind, placebo-controlled proof-of-concept trial outcomes. Alzheimers Dement. 2013;9(4):P530–1. https://doi.org/10.1016/j.jalz.2013.04.272 .

doi: 10.1016/j.jalz.2013.04.272

Audronytė E, Kaubrys G. Odor identification and discrimination as markers of early Alzheimer’s disease. Alzheimers Dement. 2022;18:e063101. https://doi.org/10.1002/alz.063101 .

doi: 10.1002/alz.063101

Hudd F, Shiel A, Harris M, Bowdler P, Wood B, Tsivos D, et al. novel blood biomarkers that correlate with cognitive performance and hippocampal volumetry: potential for early diagnosis of Alzheimer’s disease. J Alzheimers Dis. 2019;67(3):931–47. https://doi.org/10.3233/JAD-180879 .

doi: 10.3233/JAD-180879 pubmed: 30689581

Pinto JM, Wroblewski KE, Kern DW, Schumm LP, McClintock MK. Olfactory dysfunction predicts 5-year mortality in older adults. PLoS ONE. 2014;9(10):e107541. https://doi.org/10.1371/journal.pone.0107541 .

doi: 10.1371/journal.pone.0107541 pubmed: 25271633 pmcid: 4182669

Adams DR, Kern DW, Wroblewski KE, McClintock MK, Dale W, Pinto JM. Olfactory dysfunction predicts subsequent dementia in older US adults. J Am Geriatr Soc. 2018;66(1):140–4. https://doi.org/10.1111/jgs.15048 .

doi: 10.1111/jgs.15048 pubmed: 28944467

Wang W, Lee J, Harrou F, Sun Y. Early detection of Parkinson’s disease using deep learning and machine learning. IEEE Access. 2020;8:147635–46. https://doi.org/10.1109/ACCESS.2020.3016062 .

doi: 10.1109/ACCESS.2020.3016062

Lin C-H, Wang F-C, Kuo T-Y, Huang P-W, Chen S-F, Fu L-C. Early detection of Parkinson’s disease by neural network models. IEEE Access. 2022;10:19033–44. https://doi.org/10.1109/ACCESS.2022.3150774 .

doi: 10.1109/ACCESS.2022.3150774

Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Dicson S Malar (DS)

Premrutai Thitilertdecha (P)

Kanokphorn S Ruckvongacheep (KS)

Sirikalaya Brimson (S)

Tewin Tencomnao (T)

James M Brimson (JM)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH